

# Investor presentation

20 August 2020

### **Forward looking statements**



#### Disclaimer

This presentation contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Georgia Capital PLC believes that the expectations and opinions reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, which could include, among other things: impact of COVID-19; regional instability; regulatory risk across a wide range of industries; investment risk; liquidity risk; portfolio company strategic and execution risks; currency fluctuations, including depreciation of the Georgian Lari, and macroeconomic risk; and other key factors that indicated could adversely affect our business and financial performance, which are contained in our past and future filings and reports and also the 'Principal Risks and Uncertainties' and Emerging Risks included in the 1H20 Results Announcement and Georgia Capital PLC's Annual Report and Accounts 2019. No part of this presentation constitutes, or shall be taken to constitute, an invitation or inducement to invest in Georgia Capital PLC or any other entity, and must not be relied upon in any way in connection with any investment decision. Georgia Capital PLC and other entities undertake no obligation to update any forward-looking statements, whether

### Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices

### **COVID-19 statistics**




Page 4

#### Lowest number of confirmed cases and deaths per capita in the region


#### Georgia: COVID-19 response

- Border checks began on 27 February and schools switched to distance learning from 29 February;
- Travel restrictions for neighbouring countries were imposed on 5 March, followed by mandatory self-isolation/quarantine since 9 March;
- All borders were closed on 18 March and state of emergency was in place from 21 March until 22 May;
- Intracity movement was banned by the end of March;
- Six stage lockdown exit strategy, introduced from 27 April, successfully completed in the beginning of July:


#### Largely all economic activities have been resumed by mid-July, local tourism resumed from 15 June and while external borders were opened to five EU member states on 8 July



#### COVID-19 cases: dynamics in Georgia\*



#### **COVID-19 deaths since the first death case**



Total cases\*Active cases\*Quarantined\*Hospitalized\*1,3512427,235302

#### **Government measures**




#### US\$ 3 billion funding facility

- US\$ 3 billion (predominantly loans) from international donors (incl. US\$ 450m from IMF):
  - US\$1.5 billion intended for the private sector
  - US\$1.5 billion for the public sector

#### **Monetary policy**

- Easing non-price credit conditions (LTV, PTI, etc.);
- Intervening in the FX market (US\$ 270 million sold in March-July);
- Monetary policy rate reduced to 8.0% and gradual exit from strict monetary policy announced;
- Introducing US\$ 400 million currency swap facility for the financial sector to provide GEL liquidity;
- Reduced capital conservation buffer (2.5% of Risk Weighted Assets) and 2/3 of currency induced credit risk buffer total of GEL 1.6 billion;
- Temporary liquidity instrument to support credit to SMEs;
- Moratorium announced on new regulatory activity;



#### **Support measures**

- Sectoral special support packages for tourism, agriculture and real estate sectors;
- Subsidies for utility bills, basic product prices and construction materials;
- Loan restructuring for all businesses;
- VAT returns and long-term funds for banks;
- Extra funding to support business, including a credit guarantee scheme (GEL 2bln);
- Tax deferrals for car importers;
- Social aid programs to address job losses;
- Pension indexation from Jan- 21;


#### COVID-19 update | Georgia

### Macroeconomic fundamentals in 1H20



#### Monthly Economic Activity Estimate, y-o-y growth

- Economy contraction has been eased from April and GDP contraction in June was 7.7% y-o-y.
- Strong pre-COVID-19 macroeconomic fundamentals were reflected in the 1H20 GDP contraction, which was only 5.8% y-o-y.




#### **S** Exchange rate indices (1 January=100)

GEL depreciated in March and stabilised around USD/GEL 3.2 at the beginning of April, appreciating to around USD/GEL 3.05 on average since the beginning of June.



#### $\mathcal{N}$ **Fast indicators**

Merchandise trade and money transfers have recovered significantly, with remittances posting 18% y-o-y growth in June.




**Key highlights** 

- IMF forecasts that real GDP will contract by 4% in 2020, rebounding to 4% in 2021. \_
- Inflation was 6.3% on average in Jan-July. IMF forecasts average inflation at 4.7% in 2020.
- NBG decreased the monetary policy rate by 100bps to 8.0% in Apr-Jul.
- Tourism revenues fell 26% in 1Q20 and 97% in 2Q20, as international travel is halted. \_
- Official reserve assets totaled \$3.6 billion by the end of May, with reserves providing cover for 4.3 months of imports based on Q1 data.
- The fiscal deficit and public debt are expected to rise to around 8.5% and 60% in 2020 respectively, according to IMF.

### Macroeconomic fundamentals in 1H20 (cont'd)





### **Our response to COVID-19**


We implemented a cash accumulation and preservation strategy at the end of 1Q20



COVID-19 measures		Progress in 2Q20				
Limited capital allocations at GCAP level throughout the remainder of 2020, if an	!l, only critical investments ૧૪	No capital allocations in	No capital allocations in 2Q20			
Minimising capital investments at each	portfolio company level		Aggregated development capex of portfolio companies <b>GEL 30.4min</b> down 71.8% y-o-y			
Optimising Opex expenditures both at	GCAP and at portfolio companies' le	Aggregated operating expenses vel GEL 63.5min de				
GCAP liquidity remained high at 30 June 2020 GEL 280mln	Aggregated operating cash flow ge <b>GEL 87.7mln</b> +57.7% y-o-y in 2Q20		Aggregated cash balances of portfolio companies as of 30 June 2020 <b>GEL 282mIn</b> (up from GEL 183mIn at 31-Dec-19)			

#### **Rebound in revenues across all portfolio companies**





\* Aggregated like-for-like y-o-y growth numbers in portfolio companies with controlling stakes, including the revenues generated by Amboli, Alaverdi, schools, Hydrolea HPPs and Qartli wind farm before acquisition (acquired in 2H19).


### Monthly performance analysis | impact of COVID-19













\*Excluding IFRS16.













\* Electricity sales are fully covered by long-term Power Purchase Agreements (PPAs) with Government during Sep-Apr. \*\* July revenues figure is not meaningful given that schools are not operational in Jul-Aug due to holidays.






#### **Auto service**








Hospitality business: In light of the COVID-19 outbreak, operations at the existing two hotels were suspended since mid-March and both hotels are leased by the government for quarantine, while constructions of new hotels were put on hold

### Strong operating cash flow generation across portfolio companies






\*Aggregated stand-alone IFRS operating cash flow and revenue of portfolio companies with controlling stakes: private businesses and GHG (GHG's cash flow excl. IFRS 16).

### **COVID-19 impact**





Having focused on financial discipline well before COVID-19, our portfolio companies entered this crisis wellprepared and remain well-positioned to emerge stronger from the outbreak. Content




1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices

## **CGEO:LN performance**



#### LSE premium listed, with more than 90% institutional shareholder base

GCAP shareholders allocation by geography



\* Includes both vested and unvested awarded shares






\* In December 2019 GCAP issued 3.4 million new shares for acquisition of 13.6% equity stake in GHG

GCAP top shareholders	30-Jun-2020
-----------------------	-------------

Rank	Shareholder name	Ownership
1	M&G Investment Management Ltd	7.24%
2	Schroder Investment Management Ltd	4.86%
3	Norges Bank Investment Management	4.49%
4	Aberdeen Standard Investments	4.10%
5	Vanguard Group Inc	3.17%
6	Dunross & Co AB	2.91%
7	Consilium Investment Management LLC	2.75%
8	Van Eck Global	2.66%
9	Mason Hill Advisors LLC	2.56%
10	LGM Investments Ltd	2.42%
	Total	37.16%

# **Our portfolio at a glance | 30 June 2020**



1. GCAP share.


2. Total pipeline portfolio includes other pipeline projects with GEL 2 million value.

3. Different ownership stakes across premium, mid-level and affordable school segments.

4. Auto Service – 90% ownership in Amboli and 100% in Periodic Technical Inspection business.

5. GCAP's holding in GHG increased to 97.4% on 16 July 2020 as part of the Offer.

**GEORGIA** 



Multiple of Capital Invested is calculated as follows: i) the numerator is the cash and non-cash inflows from dividends and sell-downs plus fair value of investment at reporting date ii) the denominator is the gross investment amount. (1)



# **Portfolio highlights | 30 June 2020**

### Solid track record



Created three listed companies from Georgia, on the premium segment of the London Stock Exchange

**Capital raise** 

The Georgia Capital management team has a track record of executing more than 50 acquisitions in banking, healthcare. utilities. insurance. education, renewable energy, retail, FMCG and other sectors (c. 40 acquisitions were made under the **BGEO** Group)

Acquisitions

Uniquely positioned given the access to capital in a small frontier economy, where access to capital is limited:

- c.US\$ 500 million raised in equity at LSF
- Issued six Eurobonds totaling US\$ 1.75 billion
- **US\$ 3 billion**+ raised from IFIs (EBRD, IFC etc.)

Total number of acquisitions executed

Total amount of debt raised (US\$)

4.75bln+

#### 121% IRR from GHG IPO

60%+ IRR from completed m<sup>2</sup> Real Estate projects

121%

**Exit IRR** 

IRR from GHG IPO


Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices

# **Georgia Capital – Your ground floor investment opportunity**





Strong corporate governance How we run Georgia Capital




Strong board, composed solely of independent directors with extensive international experience

Approximately 40 employees at the management company level

Highly experienced management team in each portfolio company with a strong measure of independence

Solid corporate governance and oversight



Strong corporate governance

non-cash

cash

### Managing investments Share ownership plan of management in portfolio companies




Investment stage	<b>Pipel</b>	Ent	uisition/ trance	Youn	a <b>rly</b> ng Portfolio ompanies	La	Late rge Portfolio Companies	Targe	Liste Mature Portfo Companies	completion of Exit
Sector	Digital Services	Auto Service	Education	Renewable Energy	Hospitality & Commercial RE	Housing Development	P&C Insurance	<b>W</b> ater Utility	ia Healthcare Group	Bank of Georgia Group
Portfolio Company Development Focus	> Discov	very stage	Rapid g	-	ement approa anically and th stage	> Diversificatio	idance / adviso ficiency improv on of revenue of dividend d	vements streams		reholder value idend distributions
Institutionalisation/ Independence	Low									High

# **Our investment philosophy**




#### We will pick well, we will manage very well and sell extremely well



### **Capital allocations** 360-degree analysis – a strong foundation for value creation



Buying assets at attractive prices is a key part of our investment philosophy



### Capital allocations Buybacks



#### US\$45 million share buyback programme, commenced in Jun-18, was completed in Aug-19

# **US\$ 45 million**

Programme amount

**3,336,843** *Shares bought back* 

# **GBP 10.45**

Average price of shares bought back

From 1 August 2019 through 20 August 2020, we repurchased CGEO shares of up to US\$ 20 million for the management trust

### **Capital allocations** *Clear exit paths*



		Trade sale	IPO	Fund	Promote
🧶 Water Utilit	/	X	X		X
P&C Insurar	ice	X			
Housing De	velopment	Χ		X	
Renewable	Energy	X	X	X	
🚖 Hospitality	& Commercial	X		x	
Beverages		X			X
😊 Education		X	X		
Auto Service		X			
Digital servi	es	X			

# **Capital allocations**

#### How we evaluate investment performance



ROIC, MOIC and IRR combination is the key decision making matrix

#### MOIC and IRR at GCAP level

**Money multiples.** We want to know achievable money multiples with all acquisitions and analyze them in combination with the expected IRR.

**MOIC and IRR combination.** *Targeting to have a combination of high MOIC and high IRR.* 

Realised and unrealised MOICs are equally important for us.

ROIC for financing projects and reinvestment at portfolio companies' level

**ROIC.** We measure our expected return on the total invested capital at each portfolio company level.

Different yields will be appropriate for different industries, US\$ dollar and Lari businesses

Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview

# NAV Statement | 1H20



GEL '000, unless otherwise noted	Dec-19	1. Value creation	2a. Investments	2b. Buybacks	2c. Dividends	3. Operating expenses	4. Liquidity mgmt./FX/Other	Jun-20	Change %
Listed Portfolio Companies									
GHG <sup>1</sup>	430,079	(94,412)	-	-	-	-	-	335,667	-22.0%
BoG <sup>1</sup>	597,735	(203,333)	-	-	-	-	-	394,402	-34.0%
Total Listed Portfolio Value	1,027,814	(297,745)		-	-		-	730,069	-29.0%
Listed Portfolio value change %		-29.0%	-	-	-	-		-29.0%	
Private Portfolio Companies									
Late Stage	692,746	(87,574)	-	-	-	-	1,739	606,911	-12.4%
Water Utility	483,970	(46,064)	-	-	-	-	1,083	438,989	-9.8%
Housing Development	43,853	(21,958)	-	-	-	-	656	22,551	-48.6%
P&C Insurance	164,923	(19,552)	-	-	-	-	-	145,371	-11.9%
Early Stage	495,827	(80,924)	50,553	-	(4,927)	-	3,310	463,839	-6.5%
Renewable Energy	106,800	37,647	44,350	-	(4,927)	-	847	184,717	73.0%
Hospitality & Commercial RE	245,558	(110,827)	1,136	-	-	-	2,463	138,330	-43.7%
Beverages	87,119	(32,091)	5,035	-	-	-	-	60,063	-31.1%
Education	56,350	24,347	32	-	-	-	-	80,729	43.3%
Pipeline	36,696	(16,493)	5,436	-	-	-	-	25,639	-30.1%
Auto Service	25,757	(14,908)	4,200	-	-	-	-	15,049	-41.6%
Digital Services	8,790	-	-	-	-	-	-	8,790	0.0%
Other	2,149	(1,585)	1,236	-	-	-	-	1,800	-16.2%
Total Private Portfolio Value	1,225,269	(184,991)	55,989	-	(4,927)	-	5,049	1,096,389	-10.5%
Private Portfolio value change %		-15.1%	4.6%	-	-0.4%	-		-10.5%	
Total Portfolio Value (1)	2,253,083	(482,736)	55,989	-	(4,927)	-	5,049	1,826,458	-18.9%
Total Portfolio value change %		-21.4%	2.5%	-	-0.2%	-	-	-18.9%	
Net Debt (2)	(493,565)	-	(56,674)	(5,746)	4,927	(8,312)	(73,180)	(632,550)	28.2%
of which, Cash and liquid funds	211,889	-	(56,674)	(5,746)	4,927	(8,312)	646	146,730	-30.8%
of which, Loans issued	151,884	-	-	-	-	-	(18,543)	133,341	-12.2%
of which, Gross Debt	(857,338)	-	-	-	-	-	(55,283)	(912,621)	6.4%
Net other assets/ (liabilities) (3)	(5,650)		685	(287)		(6,268)	15,115	3,595	-163.6%
of which, share-based comp.	-	-	-		-	(6,268)	6,268	-	0.0%
Net Asset Value (1)+(2)+(3)	1,753,868	(482,736)		(6,033)	-	(14,580)	(53,016)	1,197,503	-31.7%
NAV change %		-27.5%	-	-0.3%	-	-0.8%	-3.0%	-31.7%	
Shares outstanding	37,441,971	_	-	222,956.0	-	-	147,002.0	37,811,929	1.0%
Net Asset Value per share	46.84	(12.9)	-	(0.4)		(0.4)	(1.5)	31.7	-32.4%
NAV per share change %		-27.5%	-	-0.9%	-	- <b>0.8</b> %	-3.1%	-32.4%	

(1) Number of shares owned in GHG and BoG were 93,011,414 and 9,784,716 as of 30-Jun-20, respectively.

# Value creation in 1H20



Portfolio Businesses	Operating Performance	Greenfields	Multiple Change and FX	Value Creation
GEL thousands	(1)	(2)	(3)	(1)+(2)+(3)
Listed				(297,745)
GHG				(94,412)
BoG			i	(203,333)
Private	(268,932)	55,482	28,459	(184,991)
Late Stage	(156,187)	-	68,613	(87,574)
Water Utility	(130,175)	-	84,111	(46,064)
Housing Development	(24,784)	-	2,826	(21,958)
P&C Insurance	(1,228)	-	(18,324)	(19,552)
Early Stage	(105,017)	57,067	(32,974)	(80,924)
Renewable Energy	4,927	32,720	I	37,647
Hospitality & Commercial Real Estate	(101,625)	-	(9,202)	(110,827)
Beverages	(8,319)	-	(23,772)	(32,091)
Education	-	24,347	-	24,347
Pipeline	(7,728)	(1,585)	(7,180)	(16,493)
Auto Service	(7,728)	-	(7,180)	(14,908)
Other	-	(1,585)	-	(1,585)
Total Portfolio	(268,932)	55,482	28,459	(482,736)

# **Capital allocations in 1H20**



			1Q20			2Q20		
GEL millions		Investments	Buybacks	Dividends	Investments	Buybacks	Dividends	Total
Listed portfolio	BOG	-	-	-	-	-	-	-
	GHG	-	-	-	-	-	-	-
	Water Utility	-	-	-	-	-	-	-
Private late stage portfolio	Housing Development	-	-	-	-	-	-	-
stage portiono	P&C Insurance	-	-	-	-	-	-	-
	Renewable Energy	44.4	-	(4.9)	-	-	-	39.5
Private early	Hospitality & Commercial RE	1.1	-	-	-	-	-	1.1
stage portfolio	Beverages	5.0	-	-	-	-	-	5.0
	Education	-	-	-	-	-	-	0.0
	Auto Service	4.2	-	-	-	-	-	4.2
Pipeline portfolio	Digital Services	-	-	-	-	-	-	-
portiono	Other	1.1	-	-	0.2	-	-	1.3
Buybacks	GCAP	-	5.7	-	-	0.3	-	6.0
	Total	56	5.7	(4.9)	0.2	0.3	-	57

#### Investments highlights

- > Renewable Energy:
  - o GEL 38.7mln for RP Global buyout (34.4% minority)
  - $\circ\,$  GEL 5.6mln for the development of under-construction Zoti HPP
- Auto Service: GEL 4.2mln mainly for the buyout of 10% ownership in Amboli, increasing GCAP's ownership to 90%
- > Beer business: GEL 5mln working capital financing

#### Dividends


> Renewable Energy: GEL 5mln dividend payment



Our liquidity remained high at GEL 280 million at 30 June 2020


## NAV per share developments in 1H20






# Liquidity management at Georgia Capital





# **Portfolio performance highlights | 1H20**





**Private early stage** 



\* Like for like figures for education business.

### **GGU issued US\$ 250 million green bonds**




### **First-ever Green Bonds from Georgia**

- > Considerable interest from investors, demonstrating our superior access to capital even during the current challenging times.
- The issuance of the bonds significantly improves the financial flexibility of GGU and enhances its liquidity profile, contributing to the healthy growth of the business.

### **Issuance details**

Notes:	US\$ 250 million, 5NC2, 7.75% Green Bonds
Listing:	Irish Stock Exchange
Notes rating:	B+ (Stable) by Fitch / B (Positive) by S&P
Sole bookrunner, Green structuring agent, Development finance structuring agent:	J.P. Morgan
Co-manager:	TBC Capital
Second party opinion provider:	Sustainalytics, a leading provider of environmental, social and governance (ESG) research and analysis, for its Green Bond Framework
Demand:	Book was oversubscribed c. 1.5x (order of up to US\$ 380m)
Call option:	Bonds can be called after 2 years at 103.875%

### Allocation by geography



### **Recommended final share exchange offer for GHG shareholders**



### Final share exchange offer for GHG shareholders was completed and our holding in GHG will reach 100% on 28 August 2020

- Further strengthening GCAP private portfolio with three strong overarching free cash flow generative businesses, being Healthcare Services, Pharmacy and Distribution, and Medical Insurance.
- > We expect to value each of these three businesses separately in the next quarters, with the valuation to be performed by an external worldwide recognized valuation firm.
- > By taking GHG private, the share of listed assets in our portfolio decreases to c. 20%, which is in line with our strategic priority announced at the investor day last year.



# **GHG agreed terms to sell HTMC hospital**



### > Divestment of one of the lowest return generating hospital, improving GHG's ROIC and leverage profile

### US\$ 12mln



**Total cash consideration** 

### **40%**



Equity stake to be sold in HTMC, subject to regulatory approvals



### **Transaction overview**

- On 19 August 2020, GHG's signed a Sales and Purchase Agreement ("SPA") to sell a 40% equity interest in High Technology Medical Centre University Clinic ("HTMC"), subject to regulatory approvals.
- Due to the HTMC's current shareholding structure (GHG owns 50%, while the other 50% is held by an individual shareholder and current CEO of the hospital) GHG has had less control on the Hospital's operations.
- > The remaining 10% interest is also intended to be disposed in the coming months.
- > The buyer, Tbilisi State Medical University, intends to use HTMC as teaching platform.
- > HTMC, had 13.0% and 9.8% share in the total healthcare services business' assets and EBITDA, respectively, in 2019.

### **Transaction rationale**

- In line with GHG's strategy to dispose low return generating assets the transaction materially improves the healthcare services business ROIC - on a pro-forma basis, increasing FY19 ROIC by 90bps.
- Improving leverage profile the total cash consideration of US\$ 12mln (GEL 36.8mln) will be used to reduce net debt position and improve leverage ratio:
  - the cost of GEL-denominated debt at c. 11.5% vs. HTMC ROIC of 3.4%.


### Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview


### Georgian healthcare market overview






#### State healthcare budget is increasing for the last several years


#### State healthcare spending dynamics





- The country's expenditure on healthcare – c.8% of GDP;
- C.40% of the total healthcare expenditure is financed by the State;
- Government expenditure on healthcare as a % of GDP reached c.3% from 1.6% in 2013;
- Government spending on healthcare accounts for c.9% of the total budget;
- In 2020 increase in Other State Healthcare Spending is due to the evolved COVID-19 pandemic.














Page 43

Listed portfolio

### **GHG at a glance** *A well diversified business model with cost and synergy advantages*





### GHG's track record of delivering strong results







EBITDA<sup>1</sup>




### **Operating cash flow**<sup>1</sup>

EBITDA to cash conversion ratio<sup>1</sup>:



CAPEX

500



### ROIC

Pursuing value creation and making and delivering strong operational performance




Note 1: Excluding IFRS16 impact

Page 45

### Healthcare services business overview

GEORGIA



6>

Other

In clinics seament revenue from out of pocket payments represents 45% of total

#### **Businesses major growth drivers**

#### **Clinics & Polyclinics**

- Increase number of registered customers
- Increasing Group referrals
  - > Adding new services, such as dental and aesthetic
  - Digitalisation


- > Building an effective logistics system for Group's healthcare facilities
- Develop retail network
- Attracting B2B clients
- **Digital Channels**

#### Ø Medium to long-term targets

- Double digit revenue CAGR in Hospitals and Clinics (20%+at Clinics)
- Gradually improving EBITDA margin
  - 28-30% at Hospitals
  - 25% at Clinics

### Healthcare services business overview (cont'd)






Note 1: Excluding IFRS16 impact

\*Sum of segments revenue does not reconcile to total revenue due to eliminations


### Pharmacy and distribution business overview





#### Operates under two pharmacy brands, each with a distinct positioning:

- GPC for the high-end customer segment
- > Pharmadepot for the mass retail segment



Note 1: Total market size 2018 - Frost & Sullivan analysis, revenue distribution between competitors represents managements estimates

#### Businesses major growth drivers

- > Expending retail footprint
- > Enhancing retail margin (private label products)
- > New retail categories such as lab service and beauty
- > Growing wholesale revenue (such as hospital supplies)
- > Digital channels

### Medium to long-term targets

- Double digit revenue CAGR
- 9%+ EBITDA margin

# Pharmacy and distribution business overview (cont'd)



Margin enhancement and strong growth in para-pharmacy sales

- Strong sales in para-pharmacy products of GEL 81.6 million in 1H20 (up 21.1% y-o-y), with 33.5% gross profit margin.
- Para-pharmacy sales have the strongest margins and the share of para-pharmacy sales in retail revenue reached 34.0% in 1H20 (30.3% in 1H19).



### GEL 33.4mln

+8.0% y-o-y Operating cash flow<sup>1</sup>

### 99.3%

-0.6 ppts y-o-y EBITDA to cash conversion<sup>1</sup>

### **GEL 33.0 mln**

+7.5% y-o-y Free cash flow<sup>1</sup>

### 55 days

-9.4% y-o-y Working capital cycle (days)


Note 1: Excluding IFRS16 impact

				Revenu	ıe				
Gross p	rofit mai	rgin (%)							Number of
		24.5%	25.5%	25.5%	24.1%	26.7%	25.2%	26.3%	
									Same store
SL	800			614.7			+8.0	)%	
nillion	600	450.3	518.6	176.9	-3.	7%	[	$\rightarrow$	
GEL millions	400	113.9	134.5		ſ	$\rightarrow$	295.2	318.8	GEL
0	200	336.4	384.1	437.8	149.4 43.4	143.8 36.6	85.5	82.9	
	0	550.4			106.0	36.6 107.2	209.7	235.9	
		2017	2018	2019	2Q19	2Q20	1H19	1H20	
				Retail		🔳 Distrik	oution		-
Numb	ber of	•			•		•		
pharn	nacies	255	270	296	279	299	279	299	

#### EBITDA<sup>1</sup>

#### **Operating leverage**<sup>1</sup>(%)






#### **Customer interactions per month**



#### Performance track record


### **Medical insurance business overview**





### Medical insurance business overview (cont'd)





Revenue (Net insurance premiums earned)



Net Profit<sup>1</sup>




Note 1: Excluding IFRS16 impact

### **Digital transformation**



### Taking healthcare beyond buildings

Successful implementation of almost all elements of the Healthcare Information System ("HIS") in all its healthcare facilities across the country:





#### Elimination of human errors and elimination of the loss of medical data or medical documents

- Real-time record of the results of clinical and administrative work
- Reduction of the time required for a comprehensive clinical review

- regulatory risks
- Daily financial and operating reports introduced in both inpatient and outpatient businesses
- Development and effective implementation of clinical quality control functions in each and every hospital

# A fully integrated digital healthcare platform

### **EKIMO – Health at your hand**

Innovative, independent and fully integrated digital healthcare platform combining all components of primary healthcare doctors, clinics, laboratories, radiology units, retail pharmacies and medical insurance.

The platform is open for any healthcare service provider or health product seller in the country, and it is completely free of charge for patients/customers.

Since its launch, EKIMO has been joined by 1,047 doctors from 73 different clinics, half of which are independent, third-party clinics.



### 51.269

**Registered users** 

33.991 Monthly active users

5.267

Monthly paying users





# Bank of Georgia (BoG) Overview

http://bankofgeorgiagroup.com/







- The first entity from Georgia to be listed on the premium segment of the Main Market of the London Stock Exchange (LSE:BGEO) since February 2012
- High standards of transparency and governance
- Leading market position<sup>1</sup> in Georgia by assets (35.4%), loans (34.8%), client deposits (38.2%) and equity (30.6%) as of 30 June 2020
- Strong brand name recognition and retail banking franchise
- Sustainable high profitability with average ROAE of more than 20% over the last four years on the back of solid NIM, low cost of credit risk and stringent cost control
- Resilient credit profile: Well-capitalised, diversified and high quality loan book and strong liquidity profile
- Dividend per share growing at 34.3% CAGR in 2010-2018 years

#### Value creation potential

- Loan book growth 15%-20%
- Maintenance of dividend pay-out ratio within 25-40%



(1) Market data based on standalone accounts as published by the National Bank of Georgia (NBG) <u>www.nbg.gov.ge</u>



### Robust capital management track record


- Capital position: aiming to maintain +200bps buffer for CET1 and Tier 1 capital ratios over minimum regulatory requirement during the medium term
- Regular dividends: Aiming 25-40% dividend payout ratio
- Cash dividend paid GEL 648mln + during 2013-2019, within the targeted payout range over past 7 years

<sup>&</sup>gt; Due to the COVID-19 related uncertainties, BoG has decided against distributing a 2019 dividend to shareholders; however, BoG's dividend policy remains unchanged, and the Bank plans to return to a targeted payout ratio range of 25-40% as soon as practically possible.

#### Listed portfolio

# Bank of Georgia (BoG) Overview (cont'd)

http://bankofgeorgiagroup.com/



(1) Actual dividend per share information for 2010-2016 years are adjusted for 19.9% Bog share issuance.

(2) Adjusted for demerger related expenses, one-off impact of re-measurement of deferred tax balance and termination costs of the former CEO. (3) ROAE adjusted for termination costs of the former CEO and executive management.

BANK OF GEORGIA



# Water utility business overview




#### Investment rationale


- Regulated monopoly in Tbilisi and surrounding districts with high entry barriers
- Sectoral output increasing at a robust growth rate (on average 9.5% in the last 10 years)
- Stable regulatory environment with fair return on investment
- Stable cash collection rates
- Diversified cash flow streams from water and electricity sales, the latter being linked to US dollars


#### Value creation potential

- EU harmonization reforms in progress in utilities sector, expected to drive water tariffs up
- Energy market deregulation positively affecting electricity sales price
- Upside opportunity from efficiency gains continued decrease in self-consumption of energy, freeing up electricity for market sales.
- Stable dividend distribution capacity

### WACC of 15.99% for the first regulation period (2018-2020)







### Water utility business overview (cont'd)



Valuation highlights   30 June 2020									
Jun-20 Dec-19 Change									
LTM EBITDA	85	95	-11.0%						
Multiple applied	9.8	8.8	11.4%						
Enterprise value	829	837	-0.9%						
Net debt	(390)	(353)	10.6%						
Equity fair value	439	484	-9.3%						
LTM ROIC <sup>1</sup>	9.7%	12.5%	-2.8ppts						
	<b>7-1</b> - (*								


Valuation peer group										
Company	Stock Exchange									
Aguas Andinas	Chile	AGUAS-A	Sant Comerc							
EASTW <sup>2</sup>	Thailand	EASTW	Thailand							
Tallinna Vesi	Estonia	TVEAT	Tallinn							

Financial metrics (GEL millions)										
	2015	2016	2017	2018	2019	1H19	1H20	Change		
Total revenue	119	127	135	149	163	75	61	-18.5%		
Of which, utility revenue	110	117	125	140	143	66	58	-11.9%		
Of which, energy revenue	9	10	10	9	20	8	2	-71.4%		
Cash flow from operations	52	54	70	82	99	45	29	-35.8%		
FCF	17	(2)	(58)	(66)	17	10	(8)	NMF		


Selected opera	ting metrics		
millions except # of connections	1H19	1H20	Change
Water Uti	lity		
Water sales (m <sup>3</sup> )	87.3	81.8	-6.3%
Self-produced electricity consumption (kwh)	86.3	85.9	-0.5%
New connections	2,312	1,441	-37.7%
Energy			
Electricity generation (kwh)	168.5	115.9	-31.2%
Energy sales (kwh)	82.2	30.0	-63.5%
Electricity purchases (kwh)	18.0	18.6	3.6%



### Performance track record



### Self-produced electricity consumption



(1) ROIC is calculated as EBITDA less depreciation, divided by aggregate amount of total equity and borrowed funds.

(2) Eastern Water Resources Dev. & Man.

### Private late stage portfolio

## Housing development business overview




#### Investment rationale


- Shortage of housing from Soviet era combined with Georgian tradition of multi generations living under one roof average household size is significantly higher at 3.3 compared to Eastern or Western Europe
- Most of the housing stock dates back to Soviet era and is amortised
- In line with the economic growth, urbanization level is expected to increase from current low level.

#### Value creation potential

- Unlock land value by developing housing projects (incl. suspended projects of defaulted company "Sveti" under distressed assets management arm)
- Earn Construction management fees from third-party projects and bring construction works in-house

### Significant room for further growth in mortgages





Page 58

# Housing development business overview (cont'd)





Valuation highlights   30 June 2020										
GEL millions, unless otherwise noted	Jun-20	Dec-19	Change							
Enterprise value	182	205	-11.1%							
Net debt	(159)	(161)	-0.9%							
Equity fair value	23	44	-48.6%							
Dividends (lifetime)	152	152	NMF							

> The cost of equity increased and the expected cash inflows from the pipeline projects decreased as a result of COVID-19 related uncertainties, leading to GEL 22.0 million negative value creation in 1H20.

Financial metrics (GEL millions) <sup>1</sup>												
	2015	2016	2017	2018	2019	1H19	1H20	Change				
Apartments sales revenue	45	96	92	95	55	16.6	33.9	NMF				
Construction revenue	-	-	-	36	60 ¦	21.6	21.7	0.29%				
EBITDA	18	11	28	16	(3)	(2.1)	3.9	NMF				
Cash flow from operations	(10)	(16)	19	(10)	(9)	(16.7)	24.5	NMF				

Ongoing residential projects update

	YTD   Jun-20		Project to da	ate   Jun-20					
	Digomi	Sveti	Digomi	Sveti					
Sq.m. of apartments sold	14,251	6,805	34,625	6,805					
Sq.m. sold as % of total available space (apartments)	60%	4.2%	60%	4.2%					
IFRS revenue recognition	36%	26%	36%	26%					
Total sales value (US\$ mln)	11.8	4.1	33.2	4.1					
Cash received (US\$ mln)	13.8 <sup>2</sup>	3.6 <sup>2</sup>	21.4	3.6					
Price per square meter US\$	832	602	958	602					

#### Performance track record

**358k sq.m** Gross Buildable Area on completed projects US\$ 63.3m

(2,856 apartments developed with 100% sales progress and US\$ 251m sales value)

**10** completed projects

3,584 apartments sold

(53.2% as a % of total with sales value<sup>3</sup> of **US\$ 293m**)

**2** on-going projects (with 3,884 apartments under development)

US\$ 55.1m dividends distributed over 7 years

(1) Housing development business' functional currency is US dollars.

2) Includes cash inflow from sales during prior periods.

3) Excluding receivable from prior period sales on Sveti project.


# **P&C insurance business overview**

#### Investment rationale


- Significantly underpenetrated P&C insurance market in Georgia (0.7% penetration)
- Market leader with a powerful distribution network of point of sale and sales agents

#### Value creation potential

- Compulsory border TPL effective from 1 March 2018
- · Local TPL expected to kick in and provide access to untapped retail CASCO insurance market with only 7% existing penetration
- Increasing footprint in untapped MSME sector, where Aldagi's revenues have grown by 62% in 1H20 from GEL 0.4m to GEL 0.6m
- Developing and introducing new digital channels to simplify purchase of insurance products
- Undisputed leader in providing insurance solutions to corporate clients









\* Market data is based on net profits reported to regulatory body and does not represent IFRS amounts.

Insurance

(1) Including healthcare insurance.






# P&C insurance business overview (cont'd)



Valuation	highlights   31	March 2020	)			Finar	ncial met	rics (GEL	. millio	ns)			
GEL millions, unless otherwise noted	Jun-20	Dec	c-19	Change		2015	2016	2017	2018	2019	1H19	1H20	Chang
					Earned premiums, net	47	50	63	67	75	36.3	34.7	-4.5%
LTM net income	18	1	8	-0.8%	Net income	12 <sup>1</sup>	14	16	18 <sup>2</sup>	18	8.3	8.2	-1.8%
Multiple applied	8.0	9	.0	-11.1%	Combined ratio	79%	73%	75%	75%	82% ¦	80.2%	80.3%	0.1ppt
			с <b>г</b>	11.00/	Loss ratio	43%	35%	40%	38%	42% ¦	41.6%	43.8%	2.2ppt
Equity fair value	141	10	65	-11.9%	Expense ratio	36%	38%	35%	37%	41%¦	38.6%	36.4%	-2.1ppt
LTM ROAE	28.7%	30.	.4%	-1.7ppts	Cash flow from operations	12	14	13	21	19 <sup>‡</sup>	14.7	9.9	-32.5%
V	aluation peer g	roup				Sel	ected op	perating	metric	S			
Company	Country	Ticker	Sto	ck Exchange					<u> </u>	,			
Dhipaya Insurance	Thailand	TIP		Thailand			1H1	9 1H2	0 0	nange (y-c	р-у)	Renewal F	Ratio
Zavarovalnica Triglav	Slovenia	ZVTG		Ljubljana	Corporate insurance policie	es written <sup>3</sup>	50,78	1 42,79	0	-15.	7%	85%	
Pozavarovalnica Sava	Slovenia	POSR		Ljubljana			, -						
Aksigorta	Turkey	AKGRT		Istanbul	Retail insurance policies w	ritten	54,73	0 49,88	7	-8.	8%	61%	
Anadolu Sigorta	Turkey	ANSGR		Istanbul									

Performance track record





1. Excluding impact of one-off FX contract with GEL 8 million loss

2. Adjusted for non-recurring items..

- 3. Excluding credit life insurance.
- 4. FY19 net income used for valuation at 31-Mar-20.

## **Renewable energy business overview**

#### Investment rationale

- Growing electricity market as supply lags behind the increasing demand, creating opportunities.
- Underutilized energy resources availability of economically feasible hydro and wind projects.
- Cheap to develop up to US\$1.5m for 1MW hydro and up to US\$1.4m for wind development on average with 1.5x higher capacity factors compared to Europe over the last decade.

#### Value creation potential

- Opportunity to establish a renewable energy platform with up to 440 MW operating capacity over the medium-term, targeting to capture approximately one third of deregulated electricity market.
- Energy consumption is expected to grow by CAGR of up to 5% over the next 10-15 years on the back of following key drivers:
  - o GDP growth with pronounced growth in electricity-heavy sectors.
- Increasing penetration of domestic appliances, with accelerating imports of electricity-intensive conventional domestic devices.
- Increasing number of installed residential and industrial air conditioning systems on the back of decreasing unit prices, expected to result in at least 5x growth in penetration level over the next decade.
- Stable dividend provider capacity in the medium term.




Growth of internal consumption: 7.7% in 2017, 6.1% in 2018 and 1.5% in 2019

Anticipated deficit of at least 6.4 TWh by 2030




### Electricity supply and consumption, LTM



#### Low base and high CDD<sup>1</sup> point towards 5x increase in AC penetration by 2030

Air conditioners are the most electricity-intensive conventional domestic devices and increasing penetration of ACs quickly eats away the surplus electricity on the market in the summer months



(1) cooling degree day

#### Actual and forecasted consumption, GWh

# **Renewable energy business overview (cont'd)**



Renewable energy platform										
Hydro: 208 MW Of which operational 71MW	26 A	Vind: 228 MW Of which operational 21M	W							
Valuation highlights   30 June 2020										
GEL millions, unless otherwise noted	Jun-20	Dec-19	Change							
Equity Fair value (GCAP share)	185	107	73.0%							
Net debt	271	239	13.3%							
GCAP ownership <sup>3</sup>	100%	65%	35ppts							

Hydrolea HPPs and Qartli wind farm (acquired in 4Q19) were valued using run-rate EBITDA earnings and related EV/EBITDA multiple, resulting in GEL 32.7 million value creation.

	Valuation pee	er group	
Company	Country	Ticker	Stock Exchange
Falck Renewables	Italy	FKR	Italy
Terna Energy	Athens	TENERGY	Athens
Azure Power Global	India	AZRE	NYSE
BCPG Public Company Limited	Thailand	BCPG	Thailand

(1) Generation capacity refers to target gross annual generation.

(2) The first phase (30MW) was launched on 8 April 2019, followed by the second phase (20MW) on 4 June 2019. Mestiachala HPPs were flooded and taken offline in late July 2019. Following the rehabilitation, 30 MW generation unit was recommissioned in December 2019, while the restoration works continue on the 20MW HPP.

(3) Following the buyout of the 34.4% minority shareholder in GRPC on 25 February 2020, Renewable Energy consists of wholly-owned hydro and wind power plants with 91MW installed capacity in aggregate.

Financial metrics (GEL millions)										
	2017	2018	2019	1H19	1H20	Change				
Revenue	NMF	NMF	16.2	2.4	18.9	NMF				
EBITDA	(1.7)	(0.8)	13.1	1.5	14.1	NMF				
Cash flow from operations	(1.5)	(0.7)	2.8	(0.6)	17.7	NMF				
Сарех	70.0	62.3	117.4	18.5	22.0	18.7%				

	1H20 performance		
GEL thousands, unless otherwise noted	Mestiachala HPPs <sup>2</sup>	Hydrolea	Qartli Wind Farm
Revenue	5,653	3,816	9,334
Of which, BI reimbursement	2,620	-	
Generation (Gwh)	25.7	26.4	46.6

#### Renewable energy projects overview | 30 June 2020

Greenfield projects	MWs	Cost per MW	Gross generation (GWh) <sup>1</sup>	Gross capacity factor	PPA tenor years	PPA tariff (US¢/kWh)	Current stage
Mestiachala HPPs	50	1.2	174	39.8%	15	5.5	Operational <sup>2</sup>
Zoti HPPs	46	1.3	173	43.0%	15	5.1	Under Construction
Darchi HPP	17	1.6	83	55.7%	10	5.6	Development
Bakhvi 2 HPP	36	1.3	136	43.2%	15	5.5	Feasibility
Racha HPPs	38	1.5	169	50.8%	-	-	Feasibility
Wind Tbilisi	54	1.3	191	40.3%	10	6.5	Development
Wind Kaspi	54	1.3	195	41.2%	10	6.5	Development
Wind (other)	99	1.4	340	39.2%	10	6.5	Feasibility
<b>Recent acquisitions</b>							
Hydrolea HPPs	21	1.8	105	58.5%	8-10	5.6	Operational
Qartli Wind Farm	21	1.4	85	47.1%	13	6.5	Operational
Total	436		1,651				

Projects under construction and under feasibility stages were put on hold in light of the COVID-19 outbreak until there is more certainty regarding the effects of COVID-19 on the business landscape and the Georgian economy.

# Hospitality and commercial real estate business overview





#### Pre Covid-19 strategy

Increased number of tourists visiting Georgia every year: 5.1 million visitors in 2019, up 6.8% y-o-y, 9.9% CAGR over the last six years.


- Tourism inflows up 1.4% y-o-y from US\$ 3.2 billion to US\$ 3.3 billion in 2019; 11.5% CAGR over the last six years.
- Grow Portfolio of rent-earning assets through residential developments/opportunistic acquisitions
- Reach more than 1,000 hotel rooms. Currently approximately 1,222 rooms are confirmed, of which 273 are
  operational, 460 are under construction and 489 are under design stage.
- Targeting mostly 3-star and 4-star hotels, mostly taping unpenetrated markets in Georgian regions

### Arrivals of tourists and tourism revenue | Georgia




### Leasable modern office stock remains scarce

Georgian office stock's significant portion is non-refurbished, soviet-era stock (traditional). Although Tbilisi's has one of the highest modern office rents among the CEE<sup>1</sup> cities.



#### ledern office rents and vields in 2019

### Hotel market overview | Tbilisi



(1) Central and Eastern Europe.

# Hospitality and commercial real estate business overview (cont'd) ( CAPITAL

Valuation highlights   30 June 2020								
GEL millions, unless otherwise noted	Jun-20	Dec-19	Change					
NAV	138	246	-43.7%					
Of which, Commercial Real Estate	77	86	-10.5%					
Of which, Hospitality	61	159	-61.6%					
LTM ROIC <sup>1</sup>	-23.7%	6.5%	-30.2ppts					

### > The mark-down of Hospitality & Commercial Real Estate NAV (8% of our total portfolio at 30 June 2020) is attributable to the uncertain outlook for the tourism sector.

Selected operating metrics									
	1H19	1H20	Change						
Gross yield (leased portfolio)	9.2%	9.2%	-0.1ppts						
Occupancy rate	84.7%	89.9%	+5.2ppts						
Leased area (sq.m.)	26,163	34,428 31.6%							
RevPAR, US\$	a Encore YTD June perf ADR, US\$	_	upancy%						
9	23	3	8.3%						
GUDAU	RI LODGE YTD June per	formance							
RevPAR, US\$	ADR, US\$	Occ	upancy%						
	36		49.1%						

In light of the COVID-19 outbreak, operations at the existing two hotels were suspended since mid-March and both hotels are rented to the government for quarantine.

### Financial metrics (GEL millions)<sup>2</sup>

	2016	2017	2018	2019	1H19	1H20	Change
NOI <sup>3</sup> from operating leases	3	3	5	6	2.8	4.2	49.8%
NOI <sup>3</sup> from hospitality services	-	-	2	2	0.7	(1.1)	NMF
Revaluation gain	-	1	28	22	7.9	(117.6)	NMF
Total net operating income	2	3	31	25 ¦	9.5	(117.6)	NMF
Cash flow from operations	3	3	6	3 ¦	0.3	(1.5)	NMF
Commercial real estate portfolio	42	42	68	129 ¦	122	118	-3.0%

### Hospitality projects overview | 30 June 2020

Hotel	Location	Rooms	Stage Pre Covid-19	Current status
Ramada Encore Kazbegi, Tbilisi	Capital city	152	Operational	Rented for quarantine
GUDAURI LODGE	Region	121	Operational	Rented for quarantine
Ramada Melikishvili, Tbilisi	Capital city	125	Construction	Put on hold
Kempinski, Tbilisi	Capital city	99	Construction	Put on hold
Seti Square in Mestia, Svaneti	Region	52	Construction	Put on hold
Ramada Kutaisi	Region	124	Construction	Put on hold
Kakheti Wine & Spa	Region	60	Construction	Put on hold
Shovi, Racha	Region	109	Design	Put on hold
Mestia, Svaneti	Region	140	Design	Put on hold
Telavi	Region	110	Design	Put on hold
Zugdidi	Region	130	Design	Put on hold
Total		1,222		

ROIC is calculated as NOI divided by aggregate amount of total equity and borrowed funds.
 Hospitality & Commercial real estate business' functional currency is US dollars.
 Net operating income.

# **Beverages business overview | Wine**




#### **Investment rationale**


- Georgia is considered the "cradle of wine" with a rich, 8,000-year history of wine-making and home to over 500 unique grape varieties
- Georgia's favorable trade regimes (free trade agreements with EU and China) provide potential for export growth for beverages
- Growing urbanization and tourism inflows are raising demand for bottled wine locally
- Strong demand in the Georgia's export markets resulted in a 9% y-o-y increase in volume in 2019, with export bottles sold reaching a 14 year high of 93 million.

#### Value creation potential

- Best-in-class distribution network platform
- Grow vineyard base to 1,000 hectares, from current 704 hectares

### Vineyard productivity – 2019 (TON/HA)





# **Beverages business overview | Beer**



#### Investment rationale

- Georgia falls behind beer consumption per capita against EU
- Georgia's favorable trade regimes (free trade agreements with EU and China) provide potential for export growth for beverages

### Value creation potential

- Best-in-class distribution network platform
- 10-year exclusivity (from 2015) from Heineken to produce and sell beer in Georgia
- One of the strongest brand equity across Georgian beer market


### Strong export market for carbonated soft drinks (CSD)

#### **Growing market**


- Export value of US\$ 27.5m (43.2m litres) in 2019.
- 33%+ CAGR in 2016-2019 years; greater organic demand from CIS countries.

### Export to more than 25 countries

• Recently more countries have been importing Georgian CSD, showing its growing popularity.



- (1) Management estimate at the end of 1H20.
- (2) Georgia 2019, other countries 2016.



#### Page 67

### Annual beer consumption (liter per capita, Age 15+) in 2019<sup>2</sup>

# **Beverages business overview (cont'd)**



	Wine business									Be	er busines	s			
	Finan	icial met	rics (GE	L millior	າs)					Financial m	etrics (GE	L millio	ns)		
	2015	2016	2017	2018	2019	1H19	1H20	Change		2017	2018	2019 ¦	1H19	1H20	Change
Wine Revenue	18	18	20	29	42	17.3	15.1	-12.6%	Beer Revenue	18	29	44	18.2	21.1	15.7%
Gross profit margin	52%	53%	49%	48%	45% ¦	45.3%	36.4%	-8.9ppts	Beer EBITDA	(6)	(14)	(6)	(6.5)	-	NMF
Wine EBITDA	2	3	5	7	9	3.0	1.3	-57.9%	Cash flow from operations	(11.4)	(13.8)	(14)	(8.8)	2.4	NMF
Cash flow from operations	2.6	1.8	1.5	0.1	2.8	1.8	4.5	NMF							
	Selecte	d operati	ing met	rics (in '	'000)				S	elected oper	ating met	rics (in	'000)		
			11	H19	1H20	Ch	ange				1H19	)	1H20	Change	
Wine sales bottles			2,	608	2,354	-	9.7%		Beer sales liters		8,464	1	11,672	37.9%	5
Of which, export	sales		2,	093	2,118		1.2%		Lemonade sales liters		1,148	3	1,238	7.8%	5
Export share (%)			80	.3%	90.0%	+9.7	' ppts		Average price per liter G	EL	2.39	)	2.27	-5.0%	5
Average price per b	oottle US\$			2.6	2.3	- 1	1.8%								
		Valuatio	n peer g	group						Valuat	ion peer <u>c</u>	group			
Company		Country	/	Ticke	er	Stoc	k Excha	nge	Company	Cour	ntry	Ticker	•	Stock Exch	ange
Purcari Wineries		Moldova Romania	-	Win	e	E	Bucharest	:	Anadolu Efes Grupa Zywiec	Turk Pola	,	AEFES ZWC		lstanbu Warsav	
Vina Concha Y Toro Vina San Pedro Bodegas Esmeralda		Chile Chile Argentin		CONCHA VSP <sup>-</sup> ESM	Т	Sa	nt Come nt Come enos Aire	rc	Turk Tuborg Cerveceria San Juan	Turk Pei	2	TBORG SNJUAN		Istanbu Lima	I


> Beverages equity fair value at GEL 60.1 million as at 30 June 2020, down by 31.1% in 1H20

> Wine businesses valued using LTM EV/EBITDA methodology, while beer business is valued with LTM EV/sales

# **Education business overview**

Fragmented education market offers attractive opportunity for a scaled player





Three high quality school partnerships across premium, mid-level and affordable education segments, providing a clear pathway to approximately more than 50% of our targeted GEL 70 million EBITDA by 2025

School	Segment	Deal close date	Total capital allocation from GCAP <sup>2</sup>	Debt/Equity	GCAP ownership	Acquired at	Current capacity of learners	Targeted capacity of learners	Targeted cost per learner (GEL)
BGA & BIST	Premium	23 July 2019	GEL 60 million	50%	70%	6.4x EV/EBITDA 2020	800	3,200	35,000 - 40,000
Buckswood	Mid-level	29 July 2019	GEL 24 million	50%	80%	6.4x EV/EBITDA 2020	760	2,980	14,000 - 19,000
Green School	Affordable	22 August 2019	GEL 21 million	50%	80% - 90% <sup>1</sup>	5.6x EV/EBITDA	1,250	5,000	6,500 - 8,500
Total			GEL 105 million				2,810	11,180	

(1) 80% equity stake in the current campus and 90% equity stake in three new schools that will be developed under green school brand.

(2) Includes actual and projected future capital allocations.


# **Education business overview (cont'd)**



Industry invest	tment ratio	nale		Medium term dema	and outlook for p	rivate high	schools
<ul> <li>Highly fragmented private school n</li> <li>Large and growing market</li> <li>Efficiency upside</li> <li>High trading multiples</li> <li>Low base – 3.8% of GDP, compared</li> <li>* Latest available data: World bank, Eurostat</li> </ul>		e of 4.6%*		currently- 10% privat Private 10% State 90%	e Currently c.570,000 learn across Georgia	in 5-years - 20 20% ers 80%	
1H20 performa	nce highlig	hts		Valuation	n highlights   30 Ju	une 2020	
Financial	metrics			Education business was value	red using ITM FV/FI	RITDA metho	odology at GEL
GEL millions, unless otherwise noted	1H19	1H20	Change				
Revenue	12.2	14.0	14.1%				
EBITDA	4.8	5.2	8.8%	business created GEL 24.3			
EBITDA margin	38.9%	37.1%	-1.8ppts	revaluation in 1H20.			
Cash flow from operations	6.3	4.9	-23.2%	Va	luation peer grou	D	
Net debt	7.1	14.8	NMF	Company	Country	Ticker	Stock exchange
Operating	, metrics			SISB Public Company Limited	Thailand	SISB	Thailand
	1H19	1H20	Change	Cogna Educação S.A.	Brazil	COGN3	Sao Paulo
Capacity utilization	85.9%	89.8%	+3.9ppts	Curro Holdings Limited	South Africa	СОН	Johannesburg
Number of learners	2,379	2,524	5.7%	Overseas Education Limited	Singapore	RQ1	Singapore
Learner to teacher ratio	9.1	8.9	-2.5%	Cairo for Investment & Real Estate	51	CIRA	Cairo and
Revenue per learner (GEL)	8,923	9,515	6.6%	Development S.A.E.	Egypt	CINA	Alexandria

# **Attractive service business – Auto Service**





Additional equity capital injection

Increased ownership by 10% to 90% in Amboli in 1Q20

**GEL 1.6mln** 

# **Auto Service business overview**

#### Investment rationale

- Georgia's Auto park continues to grow steadily, with 7.4% CAGR during the years 2012-2019
- Georgia lags behind developed countries by number of private passenger cars per capita, showing room for further growth\*
- Vehicles older than 10 years represent 90% of total auto park

#### Value creation potential

- Room for growth in the highly fragmented auto service market in Georgia with approximately GEL 2.8 billion annual revenues
- In July 2018, the business (Greenway Georgia or "GWG") won state tender to launch and operate 51 periodic technical inspection lines across Georgia with a 10-year license.
- Currently, inspection covers the basic technical control of vehicles. The government plans to gradually tighten
  procedures to try and reduce the level of harmful emissions\*
- GWG is the only player on the market with support from an international partner, Applus+, a Spainheadquartered worldwide leader in testing, inspection and certification services, present in 70+ countries

#### \* Source: GALT & TAGGART



Company	Country	Ticker	Stock Exchange
Opus Group	Sweden	OPUS	Stockholm
VICOM	Singapore	VCM	Singapore
Applus Services	Spain	APPS	Bolsa de Madrid

(1) Based on cars serviced.

(2) Combination of 2H19 and 1H21 EBITDA earnings:

(3) Combination of the last six months and the next six months earnings as of 31 December 2019.



### Valuation highlights | 30 June 2020

GEL millions, unless otherwise noted	Jun-20	Dec-19	Change				
PTI EBITDA	6.2 <sup>2</sup>	6.7 <sup>3</sup>	-7.9%				
Multiple applied	9.8	10.4	-5.8%				
PTI Enterprise Value	61	70	-13.2%				
PTI Net debt	(55)	(49)	11.5%				
PTI   Equity fair value	6	21	-72.0%				
Amboli acquisition cost	9	5	83.4%				
Auto service business   Equity fair value	15	26	-41.6%				

### **Selected metrics**

Financial metrics   Auto Service			> Mandatory testing	
	1H20	1H19	Change	suspended during
Revenue	16.0	5.3	NMF	lockdown leading to
Gross profit	3.8	3.0	25.4%	number of cars serviced
EBITDA	0.7	0.6	10.9%	down 28.5% y-o-y.
Operating cashflow	(1.4)	(0.1)	NMF	uomi 20.070 y 0 y.

### **Operating metrics | PTI**

Number of inspection lines		Market share <sup>1</sup>		
51		34%		ĺ
	1H20	1H19	Change	
Cars serviced	100,400	140,338	-28.5%	)
of which, primary	73,091	101,513	-28.0%	
of which, secondary	27,309	38,825	-29.7%	

- All inspection centers were constructed within 6 months. The operations launched in Mar-19.
- Average time per checks decreased significantly from 25 minutes upon launch to 12 minutes at 30-Jun-20.

### **Digital Services business overview**



Acquisition of Redberry enables us to have a platform for investments in the digital business



## US\$ 2.8 million new capital injected for digital start-up development



Joint ventures with corporates partnership model with minority stake of c. 20%.



Creating digital start-ups focused and applicable to Georgia (c. US\$ 0.1m per start-up)

Redberry has developed app "Lunchoba", engaged in delivering ready-food made to the offices.

### Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices

### Sovereign ratings with favourable macro fundamentals



Key Ratings Highlights										
Rating Agency	Rating	Outlook	Affirmed							
Moody's	Ba2	Stable	September 2019							
S&P Global	BB	Stable	October 2019							
<b>Fitch</b> Ratings	BB	Negative	April 2020							

### Georgia is favorably placed among peers

Country	Country Rating	Fitch Rating Outlook
Armenia	BB-	Negative
Azerbaijan	BB+	Negative
Belarus	В	Stable
Czech Republic	AA-	Stable
Georgia	ВВ	Negative
Kazakhstan	BBB	Stable
Turkey	BB-	Stable
Ukraine	В	Stable




### Georgia's key economic drivers



Liberal economic policy	<ul> <li>Top performer globally in WB Doing Business over the past 12 years</li> <li>Liberty Act (effective January 2014) ensures a credible fiscal framework:</li> <li>Fiscal deficit/GDP capped at 3%; Public debt/GDP capped at 60%;</li> <li>Business friendly environment and low tax regime (attested by favourable international rankings);</li> </ul>
Regional logistics and tourism hub	<ul> <li>A natural transport and logistics hub, connecting land-locked energy rich countries in the east and European markets in the west</li> <li>Access to a market of 2.8 billion customers without customs duties: Free trade agreements with EU, China, Hong Kong, CIS and Turkey and GSP with USA, Canada, Japan, Norway and Switzerland; FTA with Israel and India under consideration.</li> <li>Tourism inflows stood at US\$ 3.3 billion in 2019 and international travelers reached 9.4 million in 2019 (up 7.8% y-o-y), out of which tourist arrivals were up 6.8% y-o-y to 5.1 million.</li> <li>Regional energy transit corridor accounting for 1.6% of the world's oil and gas transit volumes.</li> </ul>
Strong FDI	<ul> <li>An influx of foreign investors on the back of the economic reforms have boosted productivity and accelerated growth</li> <li>FDI stood at US\$ 1.3 billion (7.2% of GDP) in 2019.</li> <li>FDI averaged 8.5% of GDP in 2010-2019.</li> </ul>
Support from international community	<ul> <li>Georgia and the EU signed an Association Agreement and DCFTA in June 2014</li> <li>Visa-free travel to the EU is another major success in Georgian foreign policy. Georgian passport holders were granted free visa entrance to the EU countries from 28 March 2017.</li> <li>Discussions commenced with the USA to drive inward investments and exports.</li> <li>Strong political support from NATO, EU, US, UN and member of WTO since 2000; Substantial support from DFIs, the US and EU.</li> </ul>
Electricity transit hub potential	<ul> <li>Developed, stable and competitively priced energy sector</li> <li>Only 20% of hydropower capacity utilized; 155 renewable (HPPs/WPPs/SPPs) energy power plants are in various stages of construction or development.</li> <li>Georgia imports natural gas mainly from Azerbaijan.</li> <li>Significantly boosted transmission capacity in recent years, a new 400 kV line to Turkey and 500 kV line to Azerbaijan built, other transmission lines to Armenia and Russia upgraded.</li> <li>Additional 2,000 MW transmission capacity development in the pipeline, facilitating cross-border electricity trade and energy swaps to Eastern Europe.</li> </ul>
Political environment stabilised	<ul> <li>Georgia underscored its commitment to European values by securing a democratic transfer of political power in successive parliamentary, presidential, and local elections and by signing an Association Agreement and free trade agreement with the EU.</li> <li>New constitution amendments passed in 2013 to enhance governing responsibility of Parliament and reduce the powers of the Presidency.</li> <li>Continued economic relationship with Russia, although economic dependence is relatively low.</li> <li>Russia began issuing visas to Georgians in March 2009; Georgia abolished visa requirements for Russians – Russia announced the easing of visa procedures for Georgians citizens effective December 23, 2015.</li> <li>Direct flights between the two countries resumed in January 2010. However, they have been banned again since July 2019 following the decision from Russia.</li> <li>Member of WTO since 2000, allowed Russia's access to WTO; In 2013 trade restored with Russia.</li> <li>In 2019, Russia accounted for 13.2% of Georgia's exports and 10.8% of imports.</li> </ul>

### Institutional oriented reforms





#### Ease of Doing Business | 2020 (WB Doing Business Report)

### Economic Freedom Index | 2020 (Heritage Foundation)




### **Corruption Perception Index | TI 2019**

Lithuania	35	
Poland	41	Georgia is on
Georgia	44 ←	
Czech Republic	44	par with EU
Latvia	44	member states
Italy	51	
Slovakia	59	
Belarus	66	
Romania	70	
Bulgaria	74	
Armenia	77	
Turkey	91	
Kazakhstan		113
Moldova		120
Ukraine		126
Azerbaijan		126
Russia		137
Uzbekistan		153

#### Business Bribery Risk, 2019 | Trace International




### Open Budget Index, 2019 | International Budget Partnership



Sources: Transparency International, Heritage Foundation, World Bank, Trace International.


### **COVID-19 impact – IMF forecasts**






Gross Domestic Product







### Fiscal Deficit (GFSM 1986, IMF Modified)

Source: IMF




**Consumer Price Inflation** 

### **Diversified resilient economy**




#### **Gross domestic product**



#### **One of the Fastest Developing Economies in the Region** Source: IMF

### Comparative real GDP growth rates, % (2007-2019 average)




#### Source: Geostat Information and Accommodation and food service communication activities 3% Industry 5% Healthcare 14% 5% Education Financial and 5% Trade insurance activities 13% 5% Construction 7% Transportation and Real estate storage 13% 7% Public administration and defence 7% Agriculture Other 9% 7%

### Monthly Economic Activity Estimate, y-o-y growth

Source: Geostat


#### Economy contraction has been eased from April and GDP contraction in June was 7.7% y-o-y



#### Diversified nominal GDP structure, 1Q2020

### **Room for further job creation**

### Unemployment rate down 1.1 ppts y-o-y to 11.6% in 2019




### Average monthly nominal earnings in business sector



### UNDP Human Development Index



#### Labor force decomposition





### **Inflation targeting since 2009**

### Inflation y-o-y vs. inflation target

Sources: NBG, GeoStat

As demand and supply shocks stemming from the pandemic move 15.0 inflation in different directions, we expect the demand side to prevail with time and inflation to decelerate towards the target by the end of 2020, reaching 3% in the 1<sup>st</sup> half of 2021.



M2 vs. inflation, y-o-y,%










### Average monthly nominal earnings

Source: Geostat

Monthly nominal earnings increased on average 7.7% y-o-y in 2010-2019



### **Current account**



#### **Current account balance (% of nominal GDP)**




Source: GeoStat 20%





#### **Exports and Re-exports, US\$ billion**

Source: NBG



### **Diversified sources of capital**




#### Strong foreign investor interest



#### Remittances

Source: NBG



Remittance inflows fell by 4.6% y-o-y in Jan-Jun 2020, reflecting an 18%


#### Visitors and tourism revenues

Sources: GNTA, NBG

2Q20 tourism revenues fell by 97% y-o-y, as borders remain closed (down 69% y-o-y in 1H20)




### **Merchandise exports**





### **Tourism sector**




### **Tourism revenues to GDP**

### Arrivals to country's population, 2017




Spending per arrival, 2017



### Number of Tourists (overnight visitors)

Source: GNTA



### **Diversified foreign trade**

### **Goods' Trade Deficit**


Source: GeoStat

In 2Q20, the trade deficit fell by 34%, as exports were cut by 23.7% and imports contracted by 29.3% on the back of the pandemic





### Electricity generation and trade, GWH






### **Diversified foreign trade**



#### Imports of Goods, contribution to growth


Source: NBG


All types of goods contributed to shrinking imports in Q2, with consumer goods driving the half of the decline




Import countries, 1H20

Sources: GeoStat





#### **Export countries, 1H20**



### Machinery and transport equipment Beverages and tobacco

- Manufactured goods
- Chemicals and related products
- Food and live animals
- Miscellaneous manufactured articles
- Commodities not classified elsewhere
- Animal and vegetable oils
- Mineral fuels, lubricants

China has become the single largest destination country for Georgian exports in 1H20 with a 13.6% share, as opposed to 2.9% in 1H19

### Prudent monetary policy ensures macro-financial stability




### **International reserves**



### Nonperforming loans to total gross loans, latest 2020



### Monetary policy rate



#### Monetary policy rate vs peers

Sources Central banks



### Floating exchange rate - policy priority







NBG monthly net interventions US\$ mn

#### Exchange rate indices (1 January=100)

Sources: NBG

Flexible exchange rate regime plays a role as a shock-absorber



Real effective exchange rate (REER)



#### **Dollarization ratios**



Page 88


### Low public debt



#### Public debt


Sources: MOF

Source: MOF



### Overall Balance, % of GDP (GFSM 2001)

0% -1.0% -1.3% -0.8% -0.7% -2.7% -2% 2.8% 4.8% -4% -6% 8.3% -8% -10% 2014 2016 2017 2018 2019 2020F 2021F 2022F 2023F 2024F Ь 201



#### **Current vs Capital Expenditure, % of GDP**

Source: MOF

Capital expenditures reached record highs in 2019 and will prove key in the fiscal stimulus, planned at GEL 3.5bln



### **Growth-oriented government reforms (2019-2020)**



Tax Reform	2 Promoting Transit & Tourism Hub
<ul> <li>Favorable tax rates for SME development</li> <li>Special tax regimes for regional offices of multinational companies</li> <li>Enhancing easiness of tax compliance</li> <li>Capital Market Reform</li> <li>Boosting stock exchange activities</li> <li>Development of local bond market</li> <li>Pension Reform</li> <li>Introduction of private pension system</li> <li>PPP Reform</li> </ul>	<ul> <li>Roads         <ul> <li>Plan to finish all spinal projects by 2020 – East-West Highway, other supporting infrastructure</li> <li>Rail             <ul> <li>Baku – Tbilisi Kars new railroad line</li> <li>Railway modernization and integration in international transport systems</li> </ul> </li> </ul> </li> </ul>
Introduction of transparent and efficient PPP framework     Public Investment Management Framework     Improved efficiency of state projects	3 Education
<ul> <li>Law of Georgia on Entrepreneurs</li> <li>New law will be drafted reflecting requirements of Association Agreement between EU and Georgia</li> <li>Responsible Lending</li> <li>Regulatory actions to support responsible lending</li> <li>Decrease household over indebtedness</li> <li>Maximizing Government Effectiveness</li> <li>Modification of government support programs based on performance</li> <li>Association Agreement Agenda</li> </ul>	<ul> <li>General Education Reform         <ul> <li>Maximising quality of teaching in secondary schools</li> </ul> </li> <li>Fundamental Reform of Higher Education         <ul> <li>Based on the comprehensive research of the labour market needs</li> <li>Improvement of Vocational Education             <ul> <li>Increase involvement of the private sector in the professional education</li> </ul> </li> </ul></li></ul>

### Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices
	<ul> <li>Georgia Capital results discussion</li> <li>Georgia Capital financial statements</li> <li>Portfolio companies overview</li> <li>Portfolio companies financial statements</li> </ul>

### Maturity profile across portfolio companies



Gross debt maturity as of 30 June 2020 <sup>1</sup>									
Gel millions, unless otherwise noted	2H20	2021	2022	2023	2024	2024+	Total		
GHG	70	94	181	33	77	-	455		
Late Stage	-	29	121	2	31	481	664		
Water Utility	-	-	-	-	-	477	477		
Housing development <sup>2</sup>	-	29	121	2	31	4	187		
P&C Insurance	-	-	-	-	-	-	-		
Early Stage	7	144	43	35	51	375	655		
Renewable Energy	-	-	-	-	-	287	287		
Hospitality	1	27	9	10	26	45	118		
Commercial Real Estate <sup>3</sup>	-	92	-	-	-	-	92		
Wine	5	5	9	9	9	17	54		
Beer	-	17	22	12	13	19	83		
Education	1	3	3	4	3	7	21		
Pipeline	3	6	7	7	14	17	54		
Auto Service	3	6	7	7	14	17	54		
Total	80	273	352	77	173	873	1,828		

> All existing loans of Water Utility and Renewable Energy were refinanced by GGU's green bond, shifting principal payments through 2020-2023 to 2024+

> Beer business' loan terms renegotiated, shifting principal payments from 2H20 to the following years

(1) Principal repayments as of 30 June 2020, considering green bonds issued by GGU in July 2020.

(2) A 3-year US\$ 35 million bonds issued on the local market in Oct-19 with a 7.5% annual coupon rate, maturing in Oct-22.

(3) A 3-year US\$ 30 million bonds issued on the local market in 2019 with a 7.5% annual coupon rate, maturing in Dec-21. Bonds are backed by commercial real estate.

### Multiple of Invested Capital (MOIC) | 30 June 2020



GEL millions	Gross Investment	Sell down	Dividends	Fair Value	моіс	Realized MOIC
	(1)	(2)	(3)	(4)	(2+3+4) / (1)	(2+3) / (1)
Listed Investments	381	418	138	730	3.4x	1.5x
Georgia Healthcare Group PLC	252	131	4	336	1.9x	0.5x
Bank of Georgia Group PLC	129	287	134	394	6.3x	3.3x
Private investments, late stage	318	-	270	607	2.8x	0.8x
Water Utility	215	-	82	439	2.4x	0.4x
Housing Development	93	-	152	23	1.9x	1.6x
P&C Insurance	10	-	36	145	17.8x	3.5x
Private investments, early stage	560	-	5	464	0.8x	-
Renewable Energy	144	-	5	185	1.3x	-
Hospitality and Commercial Real Estate	197	-	-	138	0.7x	-
Beverages	162	_	_	60	0.4x	-
Education	56	_	_	81	1.4x	-
Pipeline	25	-	-	26	1.0x	-
Auto Service	14	-	-	15	1.4x	-
Digital Services	9	_	_	9	1.0x	-
Other	2	-	-	2	1.0x	-
Total	1,283	418	413	1,826	2.1x	0.6x


### **Net Asset Value evolution**





(1) Components do not sum up, as NAV also includes net other assets/liabilities.

### Acquisitions in 2019 | private portfolio



(1) 80% equity stake in the current campus and 90% equity stake in three new schools that will be developed under green school brand.

(2) Includes actual and projected future capital allocations.

(3) An additional earn-out may apply subject to EBITDA target within the next three academic years. The cumulative EV paid will not exceed 5.6x EV/EBITDA of the respective year (including performance-related deferred consideration).

GEORGIA

### Georgia Capital's board of directors





### Board of directors - Georgia Capital PLC





**Caroline Brown**, Independent Non-Executive Director Experience: A Fellow of the Chartered Institute of Management Accountants and has over 20 years experience sitting on the boards of listed companies, and has chaired audit committees of listed companies for the past 15 years.



**Jyrki Talvitie**, Independent Non-Executive Director Experience: 28 years of experience in the banking, including Sberbank, VTB, East Capital and Bank of New York in both buy and sell-side transactions



**Maria Chatti-Gauttier**, Independent Non-Executive Director Experience: Over 25 years of experience in private equity in prominent financial institutions. Currently Partner of Trail Management,



### David Morrison, Senior Independent Director

Experience: formerly Director at Sullivan & Cromwell with a track record of over 28 years, Founding CEO of the Caucasus Nature Fund (CNF)



**Kim Bradley**, Independent Non-executive Director Experience: Goldman Sachs AM, Senior Executive at GE Capital, President of Societa Gestione Crediti, Board Chairman at Archon Capital Deutschland



Massimo Gesua'sive Salvadori, Independent Non-Executive Director

Experience: currently an analyst at Odey asset management, formerly with McKinsey & Company for over 9 years

### 6 out of 7 members are independent

### Georgia Capital's highly experienced management team



### Georgia Capital Management



GGU

orgia

#### Archil Gachechiladze, CEO, Bank of Georgia

Previously CEO at GGU, the Group's water utility and renewable businesses. Prior to that Archil was a Deputy CEO in charge of corporate banking in BoG. He launched the Bank's industry and macro research, brokerage, and advisory businesses. Previously, he was an Associate at Lehman Brothers Private Equity in London, and worked at Salford Equity Partners, EBRD, KPMG, Barents, and the World Bank. Holds MBA with distinction from Cornell University and is CFA charterholder.

#### Giorgi Vakhtangishvili, CEO, Georgia Global Utilities

Formerly CFO at GGU. Previously held different managerial positions at BGEO Group's companies; before joining GGU, Giorgi served as CEO of m<sup>2</sup>. Previously he was a senior auditor at EY Georgia. Holds BBA degree from European School of Management (ESM).

#### Irakli Burdiladze, Co-CEO, Georgia Real Estate\*

Joined as a CFO at the Bank of Georgia in 2006. Before taking leadership of real estate business in 2010, he served as the COO of the Bank. Prior he was a CFO at a leading real estate developer and operator in Georgia. Holds a graduate degree in International Economics and International Relations from the Johns Hopkins University School of Advanced International Studies.

#### Shota Berekashvili, Co-CEO, Georgia Real Estate\*

Joined JSC m<sup>2</sup> Real Estate in 2017. Before joining m<sup>2</sup> from 2009 to 2017 Shota was the founder and the CEO of "BK Capital" construction company. From 2003 to 2009 worked in Moscow as CFO of "BK Capital". From 1999 to 2003 worked in investment banking sector in NY and London. In 1999 Shota graduated from Columbia University NY with Bachelor's degree in Science and in 2002 Shota graduated from Cass Business School London with Master's Degree in Corporate Finance and Risk Management.

#### Giorgi Baratashvili, CEO, Aldagi

Joined as the Head of Corporate Clients Division of Aldagi in 2004. Before taking the leadership of our P&C insurance business in 2014, he served as Deputy CEO of Aldagi in charge of strategic management for corporate sales and corporate account management. Holds the Master Diploma in International Law.

#### Temo Jankarashvili, CEO, Wine Business

CEO of Wine business since November 2019, in addition to his CFO role at beer business. Formerly CFO at Rustavi Azot JSC. He has an extensive experience in finance. Previously, worked for BGEO Group for 11 years, served as a VIP Director at Bank of Georgia, successfully leading the commercial lending team, covering structured financing, M&As, LBOs and project financing. Holds BBA degree in Banking and Finance from Tbilisi State University.

#### Tornike Nikolaishvili, CEO, Beer Business

CEO of beer business since September 2018, having previously been Chief Marketing Officer at Bank of Georgia from March 2018. Previously he was a Commercial Director at EFES Georgia – Natakhtari Brewery. Before joining EFES, he was an Advertising Manager of Cartu-Universal. Overall, he has 15 years' experience in FMCG sector. Holds BBA degree of European School of Management.

\* m<sup>2</sup> was renamed as Georgia Real Estate in 2019



#### Irakli G Formerl

#### Irakli Gilauri, Chairman & CEO

Formerly CEO of BGEO Group since 2011, joined as CFO of Bank of Georgia in 2004. Mr Gilauri was appointed Chairman of the Bank in September 2015, having previously served as CEO of the Bank since May 2006. Up to 20 years of experience in the banking, investment and finance. Prior, he was EBRD (European Bank for Reconstruction and Development) banker. Over the last decade, Irakl's leadership has been instrumental in creating major players in a number of Georgian industries, including banking, healthcare, utilities and energy, real estate, insurance and wine. Holds an MS in banking from CASS Business School.



#### Avto Namicheishvili, Deputy CEO

Avto also serves as a chairman of the Group's water utility, renewable energy and beverages businesses. Formerly he was BGEO Group General Counsel. Joined as a General Counsel at the Bank of Georgia in 2007, and has since played a key role in all of the Group's equity and debt raises on the capital markets, and over 25 mergers and acquisitions. Prior, was a Partner at a leading Georgian law firm. Holds LL.M. in international business law from Central European University, Hungary.



#### Nikoloz Gamkrelidze, Deputy CEO

Nick also serves as a CEO of the Georgian Healthcare Group. Previously deputy CEO (Finance) of BGEO Group. Our healthcare business story starts with Nick, who started it in 2006, and has successfully led it through outstanding growth and most recently the IPO on the London Stock Exchange. Holds an MA in international healthcare management from the Tanaka Business School of Imperial College London



#### Giorgi Alpaidze, Chief Financial Officer

Formerly BGEO Group CFO. Joined BGEO as Head of Group's Finance, Funding and Investor Relations in 2016. He has extensive international experience in banking, accounting and finance. Previously he was a senior manager in Ernst & Young LLP's Greater New York City's assurance practice. BBA from the European School of Management in Georgia. U.S. Certified Public Accountant.

#### Ia Gabunia, Chief Exit Strategy Officer Formerly Investment Director at Georg

Formerly Investment Director at Georgia Capital. Joined BGEO as an Investment Director in 2017. Ia has over 10 years of experience in banking and investment management. Prior to joining BGEO la served as Head of Corporate Banking at Bank Republic, Societe Generale Group. Previously la held numerous executive positions in the leading Georgian companies, la holds a BSc degree from London School of Economics and Political Science, UK.

#### Nikoloz Gamkrelidze, CEO, Georgia Healthcare Group

Previously deputy CEO (Finance) of BGEO Group. Our healthcare business story starts with Nick, who started it in 2006, and has successfully led it through outstanding growth and most recently the IPO on the London Stock Exchange. Holds an MA in international healthcare management from the Tanaka Business School of Imperial College London.

# Private









### Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices
	<ul> <li>Georgia Capital results discussion</li> <li>Georgia Capital financial statements</li> <li>Portfolio companies overview</li> <li>Portfolio companies financial statements</li> </ul>

### NAV Statement | 2Q20



GEL '000, unless otherwise noted	Mar-20	1. Value creation	2a. Investments	2b. Buybacks	2c. Dividends	3. Operating expenses	4b. Liquidity mgmt./FX/Other	Jun-20	Change %
Listed Portfolio Companies	660,067	70,002	-	-	-	-	-	730,069	10.6%
GHG <sup>1</sup>	295,455	40,212	-	-	-	-	-	335,667	13.6%
BoG <sup>1</sup>	364,612	29,790	-	-	-	-	-	394,402	8.2%
Private Portfolio Companies	1,139,711	(48,340)	204	-	-	-	4,814	1,096,389	-3.8%
Late Stage	613,323	(7,916)	-	-	-	-	1,504	606,911	-1.0%
Water Utility	432,301	5,840	-	-	-	-	848	438,989	1.5%
Housing Development	39,921	(18,026)	-	-	-	-	656	22,551	-43.5%
P&C Insurance	141,101	4,270	-	-	-	-	-	145,371	3.0%
Early Stage	500,918	(40,421)	32	-	-	-	3,310	463,839	-7.4%
Renewable Energy	151,150	32,720	-	-	-	-	847	184,717	22.2%
Hospitality & Commercial RE	218,623	(82,756)	-	-	-	-	2,463	138,330	-36.7%
Beverages	74,795	(14,732)	-	-	-	-	-	60,063	-19.7%
Education	56,350	24,347	32	-	-	-	-	80,729	43.3%
Pipeline	25,470	(3)	172	-	-	-	-	25,639	0.7%
Auto Service	15,052	(3)	-	-	-	-	-	15,049	0.0%
Digital Services	8,790	-	-	-	-	-	-	8,790	0.0%
Other	1,628	-	172	-	-	-	-	1,800	10.6%
Total Portfolio Value (1)	1,799,778	21,662	204	-	-	-	4,814	1,826,458	1.5%
Net Debt (2)	(659,596)	-	(889)	-	-	(3,934)	31,869	(632,550)	-4.1%
of which, Cash and liquid funds	170,109	-	(889)	-	-	(3,934)	(18,556)	146,730	-13.7%
of which, Loans issued	135,878	-	-	-	-	-	(2,537)	133,341	-1.9%
of which, Gross Debt	(965,583)	-	-	-	-	-	52,962	(912,621)	-5.5%
Net other assets/ (liabilities) (3)	(2,846)	-	685	(287)	-	(2,636)	8,679	3,595	NMF
Of which, share-based comp.	-	-	-	-	-	(2,636)	2,636	-	0.0%
Net Asset Value (1)+(2)+(3)	1,137,336	21,662		(287)	-	(6,570)	45,362	1,197,503	5.3%
NAV change %		1.9%	-	0.0%	-	-0.6%	4.0%	5.3%	
Shares outstanding	37,686,056	-	-	(21,129)	-	-	147,002	37,811,929	0.3%
Net Asset Value per share	30.18	0.57	-	0.01	-	-0.17	1.08	31.67	4.9%
NAV per share change %		1.9%	-	0.0%	-	-0.6%	3.6%	4.9%	

(1) Number of shares owned in GHG and BoG were 93,011,414 and 9,784,716 as of 30-Jun-20, respectively.

### Georgia Capital 1H20 performance (adjusted IFRS10 accounts)



Income statement								
GEL '000, unless otherwise noted	1H20	1H19	Change					
Dividend income	4,927	55,667	-91.1%					
Interest income	11,816	21,868	-46.0%					
Realised / unrealised (loss)/ gain on liquid funds	(4,577)	5,297	NMF					
Interest expense	(30,180)	(25,892)	16.6%					
Gross operating (loss)/income	(18,014)	56,940	NMF					
Operating expenses	(14,580)	(16,609)	-12.2%					
GCAP net operating (loss)/income	(32,594)	40,331	NMF					
Fair value changes of portfolio companies								
Listed portfolio companies	(297,745)	216,885	NMF					
Of which, Georgia Healthcare Group PLC	(94,412)	141,081	NMF					
Of which, Bank of Georgia Group PLC	(203,333)	75,804	NMF					
Private portfolio companies	(189,918)	74,034	NMF					
Late Stage	(87,574)	52,948	NMF					
Of which, Water Utility	(46,064)	28,689	NMF					
Of which, Housing Development	(21,958)	(6,626)	NMF					
Of which, P&C Insurance	(19,552)	30,885	NMF					
Early Stage	(85,851)	5,424	NMF					
Of which, Renewable energy	32,720	-	NMF					
Of which, Hospitality & Commercial Real Estate	(110,827)	7,087	NMF					
Of which, Beverages	(32,091)	(1,663)	NMF					
Of which, Education	24,347	-	NMF					
Pipeline businesses	(16,493)	15,662	NMF					
Of which, Auto Service	(14,908)	15,662	NMF					
Of which, other	(1,585)	-	NMF					
Total investment return	(487,663)	290,920	NMF					
(Loss)/Income before foreign exchange movements and non-recurring expenses	(520,257)	331,251	NMF					
Net foreign currency loss	(41,361)	(25,624)	61.4%					
Non-recurring expenses	(3,222)	-	NMF					
Net (loss)/Income	(564,840)	305,627	NMF					

### Reconciliation of adjusted IFRS10 accounts to IFRS

GEL '000, unless otherwise noted	Income statement (Adjusted IFRS10 accounts)	Adjustment	IFRS income statement
Dividend income	4,927	(4,927)	-
Interest income	11,816	(11,816)	-
Realised / unrealised (loss)/ gain on liquid funds	(4,577)	4,577	-
Interest expense	(30,180)	30,180	-
Gross operating (loss)/income	(18,014)	18,014	-
Operating expenses	(14,580)	10,890	(3,690)
GCAP net operating (loss)/income	(32,594)	28,904	(3,690)
Total investment return / gross investment loss	(487,663)	(62,929)	(550,592)
(Loss)/Income before foreign exchange movements and non-recurring expenses	(520,257)	(34,025)	(554,282)
Net foreign currency loss	(41,361)	41,165	(196)
Non-recurring expenses	(3,222)	3,222	-
Net (loss)/Income	(564,840)	10,362	(554,478)

### Content




1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices
	<ul> <li>Georgia Capital results discussion</li> <li>Georgia Capital financial statements</li> <li>Portfolio companies overview</li> </ul>

> Portfolio companies financial statements

### Georgian healthcare market overview







Overview	<ul> <li>UHC was introduced in February 2013 and replaced most of the previously existing state-funded medical insurance plans</li> <li>The main goal is to provide basic healthcare coverage to the entire population</li> </ul>
Financing and top-up mechanism	<ul> <li>UHC is fully financed by the government</li> <li>UHC doesn't reimburse 100% of costs in most cases, leaving substantial room for out-of-pocket payments by patients</li> </ul>
Beneficiaries and providers	<ul> <li>UHC beneficiaries may select any healthcare provider enrolled in the programme</li> <li>Actual prices charged to patients by healthcare providers are not regulated by the state</li> <li>Any provider, whether private or public, is eligible to participate in the programme</li> </ul>

# Housing development business | Overview of completed and on-going projects as of 30 June 2020



#	Project name	Total Sq.m. (Net Sellable Area)	Number of apartments	Sq.m. of apartments sold	Number of apartments sold	apartments	Number of apartments available for sale	sq.m. apartments available for sale	Number of apartments transferred to IP	Sq.m. of apartments transferred to IP		Actual / Planned Completion date (construction)	Construction progress	Total Sales (US\$ mln)	Recognised as revenue (US\$ mln)		Deferred revenue expected to be recognised as revenue in 2020	Land value unlocked (US mln)	\$ Realised & Expected IRR
Compl	eted projects	218,397	2,856	218,397	2,856	100.0%	-	-	21	3,337				250.7	250.7	-	-	32.9	
1	Chubinashvili street	9,366	123	9,366	123	100.0%	-	-	-	-	Sep-10	Aug-12	100%	9.9	9.9	-	-	0.9	47%
2	Tamarashvili street	40,717	525	40,717	525	100.0%	-	-	-	-	May-12	Jun-14	100%	48.9	48.9	-	-	5.4	46%
3	Kazbegi Street	21,937	295	21,937	295	100.0%	-	-	-	-	Dec-13	Feb-16	100%	27.2	27.2	-	-	3.6	165%
4	Nutsubidze Street	15,757	221	15,757	221	100.0%	-	-	-	-	Dec-13	Sep-15	100%	17.4	17.4	-	-	2.2	58%
5	Tamarashvili Street II	21,023	266	21,023	266	100.0%	-	-	4	476	Jul-14	Jun-16	100%	24.3	24.3	-	-	2.7	71%
6	Moscow avenue	15,053	238	15,053	238	100.0%	-	-	-	-	Sep-14	Jun-16	100%	12.3	12.3	-	-	1.6	31%
7	Skyline	2,614	12	2,614	12	100.0%	-	-	7	1,375	Dec-15	Dec-17	100%	5.4	5.4	-	-	3.1	329%
8	Kartozia Street	58,443	801	58,443	801	100.0%	-	-	-	-	Nov-15	Nov-18	100%	61.1	61.1	-	-	5.8	37%
9	50 Chavchavadze ave.	6,550	77	6,550	77	100.0%	-	-	5	741	Oct-16	Nov-18	100%	10.9	10.9	-	-	3.3	27%
10	Kazbegi Street II	26,937	298	26,937	298	100.0%	-	-	5	744	Jun-16	Jun-19	100%	33.2	33.2	-	-	4.3	43%
On-go	ing projects	221,343	3,884	43,957	728	18.7%	3,156	177,386	-	-				58.1	21.6	36.5	13.9	30.4	
11	10 Melikishvili ave.	2,527	16	2,527	16	100.0%	-	-	-	-	Sep-17	Sep-20	99%	4.4	4.1	0.3	0.3	0.8	101%
12	m3 Saburtalo, Stage I	22,089	391	21,505	380	97.2%	11	584	-	-	Jul-19	Sep-21	29%	22.0	9.7	12.4	6.5	2.5	112%
13	m3 Saburtalo, Stage II	36,415	562	13,119	216	38.4%	346	23,296	-	-	Feb-20	May-22	2%	11.9	2.6	9.3	2.8	4.6	132%
14	Sveti Nutsubidze	22,591	411	3,834	62	15.1%	349	18,757	-	-	Mar-20	Apr-23	0%	4.9	1.5	3.4	1.4	5.7	
15	Sveti MIrtskhulava	89,297	1,624	2,606	48	3.0%	1,576	86,691	-	-	Mar-20	Apr-23	1%	8.6	2.2	6.4	1.5	11.9	
16	Sveti Chkondideli	48,423	880	365	6	0.7%	874	48,059	-	-	Mar-20	Apr-23	1%	6.3	1.5	4.8	1.4	5.0	
	Total	439,739	6,740	262,354	3,584	53.2%	3,156	177,386	21	3,337				308.8	272.3	36.5	13.9	63.3	

### **P&C insurance business | segment results in 1H20**





Supervision Service of Georgia. Market shares by earned premium

(2) Motor own damage, motor third party liability insurance.

(3) Contractor's all risks insurance (CAR), Commercial property, Household Property, Machinery breakdowns insurance.

(4) Loan-linked life insurance.

(5) Financial risk, employer's liability, professional indemnity. General third party liability insurance (GTPL). Freight Forwarders' liability (FFL), Household GTPL, Product liability

(6) Carao, Contractor's Plant And Machinery insurance (CPM), Livestock, Bankers blanket bond insurance (BBB), Directors and officers liability Insurance (D&O), Agro insurance.


**Page 104** 

### Hospitality and commercial RE business | commercial portfolio & hotel portfolio highlights





Key performance metrics of hotels | Tbilisi



### Content



1.	COVID-19 update
2.	Georgia Capital at a glance
3.	Georgia Capital strategy & capital allocations
4.	Georgia Capital 1H20 results discussion and key developments
5.	Portfolio overview
6.	Georgian macro overview
7.	Appendices
	<ul> <li>Georgia Capital results discussion</li> <li>Georgia Capital financial statements</li> <li>Portfolio companies overview</li> </ul>

> Portfolio companies financial statements

### **GHG Consolidated financial highlights**



Revenue, gross         474,522         472,872         0.3%         214,469         237,660         9.87           Corrections & rebates         (1,593)         (1,164)         36.9%         (636)         (605)         5.17           Revenue, net         472,929         471,708         0.3%         213,833         237,055         -9.88           Costs of services         (326,096)         (321,660)         1.4%         (146,393)         (163,163)         -10.33           Cost of materials and supplies         (51,608)         (55,533)         -8.7%         (23,100)         (28,578)         -19.11           Cost of materials and supplies         (1,139)         (1,869)         -39.1%         (1,971)         (12,064)         -0.82           Cost of materials and supplies         (1,9863)         (23,440)         -15.3%         (8,647)         (11,812)         -26.83           Agents, brokers and employee commissions         (1,196)         (1,415)         -15.5%         (551)         (646)         -14.77           Cost of pharma – retail         (167,006)         (149,730)         11.5%         (7,721)         (7,636)         -0.88           Gross profit         146,833         150,048         -2.1%         67,440         73.892		Income stat	ement				
Corrections & rebates       (1,593)       (1,164)       36.9%       (626)       (605)       5.13         Revenue, net       (326,096)       (321,660)       1.4%       (146,393)       (164,393)       (163,163)       -10.33         Cost of salaries and other employee benefits       (51,608)       (56,513)       -8.7%       (23,120)       (22,578)       -9.88         Cost of medical service providers       (1,139)       (1,864)       -3.91%       (374)       (1,070)       -6.50%         Cost of medical services and employee commissions       (1,196)       (1,415)       -15.5%       (515)       (646)       -14.7%         Cost of pharma – wholesale       (51,220)       (56,416)       -9.2%       (22,709)       (29,184)       -22.2%         Cost of pharma – wholesale       (1,196)       (1,49,730)       11.5%       (75,201)       (76,366)       -0.88         Gross profit       1046,833       150,048       -2.1%       67,440       73,892       -8,77         Salaries and other exployee benefits       (49,589)       (47,317)       1.04%       (10,030)       0.66         Gross profit       1046,833       150,048       -2.1%       67,440       73,862       -8,77         Salaries and other exployee benefits<	GEL thousands, unless otherwise noted	1H20	1H19	Change	2Q20	2Q19	Change
Revenue, net         472 292         471 708         0.33%         213 833         237 055         9-98           Costs of services         (326,096)         (321,660)         1.4%         (146,393)         (163,163)         -10.33           Cost of salaries and other employee benefits         (51,600)         (56,533)         -8.7%         (374)         (128,578)         -19.15           Cost of materials and supplies         (26,322)         (24,477)         7.5%         (11,971)         (12,064)         -0.8%           Cost of materials and supplies         (27,39)         (7,730)         -0.5%         (3.300)         (3.443)         -4.22           Net insurance claims incurred         (19,863)         (23,440)         -15.3%         (55,51)         (646)         -14.7%           Cost of pharma – victail         (167,006)         (14,9730)         11.5%         (75,721)         (76,366)         -0.8%           General and administrative expenses         (21,753)         (19,710)         10.4%         (10,000)         (10,030)         0.66           General and administrative expenses excluding IFRS 16         (33,02)         (30,007)         9.7%         (15,364)         (15,200)         0.55           Impairment of receivables         (21,753)         (19,710)	Revenue, gross	474,522	472,872	0.3%	214,469	237,660	-9.8%
Costs of services         (326, 696)         (321, 660)         1.4%         (146, 593)         (163, 163)         -10.33           Cost of salaries and other employee benefits         (51, 608)         (56, 533)         -8.7%         (23, 120)         (28, 578)         -19.13           Cost of medical service providers         (1, 139)         (1, 869)         -39.1%         (374)         (1, 070)         -550           Cost of utilities and other         (7, 739)         (7, 760)         -0.5%         (3, 300)         (3, 443)         -4.27           Cost of utilities and other         (7, 739)         (7, 760)         -0.5%         (3, 400)         -15.3%         (8, 647)         (11, 812)         -26.8%           Agents, brokers and employee commissions         (1, 196)         (14, 730)         11.5%         (75, 721)         (76, 366)         -0.8%           Gross profit         146, 833         150, 048         (24, 123)         (23, 222)         0.87           General and administrative expenses         (21, 753)         (19, 710)         10.4%         (10, 090)         (10, 030)         0.66           General and administrative expenses         (21, 753)         (19, 710)         10.4%         (15, 564)         (15, 250)         0.55           Impairment of receiva	Corrections & rebates	(1,593)	(1,164)	36.9%	(636)	(605)	5.1%
Cost of salaries and other employee benefits       (51,608)       (56,533)       -8.7%       (22,120)       (28,578)       -19.13         Cost of materials and supplies       (26,325)       (24,477)       7.5%       (11,971)       (12,064)       -0.83         Cost of medical service providers       (1,139)       (1,869)       -0.5%       (3,300)       (3,443)       -4.27         Net insurance claims incurred       (7,739)       (7,770)       -0.5%       (3,300)       (3,443)       -4.27         Cost of pharma – wholesale       (51,220)       (56,416)       -9.2%       (22,709)       (29,184)       -22.25         Cost of pharma – vetrail       (167,006)       (149,730)       11.5%       (57,721)       (76,366)       -0.88         General and administrative expenses       (21,753)       (19,710)       10.4%       (24,123)       (23,922)       0.88         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.65         Inpairment of receivables       (3,310)       (2,312)       43.2%       (1,995)       (1,140)       7.50         Depreciation and administrative expenses       (21,753)       (19,710)       10.4%       (24,123)       (23,222)       0.88 </td <td>Revenue, net</td> <td>472,929</td> <td>471,708</td> <td>0.3%</td> <td>213,833</td> <td>237,055</td> <td>-9.8%</td>	Revenue, net	472,929	471,708	0.3%	213,833	237,055	-9.8%
Cost of materials and supplies       (26,325)       (24,477)       7.5%       (11,971)       (12,064)       -0.88         Cost of medical service providers       (1,139)       (1,769)       -39.1%       (374)       (1,070)       -65.07         Cost of utilities and other       (7,739)       (7,780)       -0.5%       (3,300)       (3,443)       -4.22         Net insurance claims incurred       (19,863)       (23,440)       -15.3%       (8,647)       (11,812)       -26.83         Agents, brokers and employee commissions       (11,96)       (14,1415)       -15.5%       (551)       (646)       -14.47         Cost of pharma - wholesale       (51,220)       (56,416)       -9.2%       (22,709)       (29,184)       -22.28         Cost of pharma - wholesale       (21,753)       (19,710)       10.4%       (24,123)       (23,922)       0.86         General and administrative expenses       (21,753)       (19,710)       10.4%       (14,000)       0.60         General and administrative expenses       (21,753)       (3,300)       (2,317)       4.8%       (24,262)       25.95         EBITDA       (33,012)       (3,232)       (30,097)       9.7%       (15,364)       (15,290)       0.57         Cher operating in	Costs of services	(326,096)	(321,660)	1.4%	(146,393)	(163,163)	-10.3%
Cost of medical service providers       (1,139)       (1,869)       -39.1%       (374)       (1,070)       -65.00         Cost of tuilities and other       (7,739)       (7,780)       -0.5%       (3,300)       (3,443)       -4.25         Agents, brokers and employee commissions       (1,196)       (1,415)       -15.5%       (551)       (646)       -14.7         Cost of pharma – wholesale       (167,006)       (149,730)       11.5%       (75,721)       (76,366)       -0.88         Gots of pharma – vertail       (167,006)       (149,730)       11.5%       (75,721)       (76,366)       -0.88         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.66         General and administrative expenses excluding IFRS 16       (33,023)       (23,023)       (30,097)       9.7%       (15,364)       (12,90)       0.55         BITDA       1,658       4,454       -62.8%       333       3.826       -91.35         EBITDA excluding IFRS 16       13.2%       15.8%       -26.6pts       12.3%       15.66       4.26.26       -25.96         EBITDA receveraling income       (29,185)       (26,809)       8.9%       (14,666)       (13,63)       7.7	Cost of salaries and other employee benefits	(51,608)	(56,533)	-8.7%	(23,120)	(28,578)	-19.1%
Cost of utilities and other       (7,739)       (7,780)       -0.5%       (3,300)       (3,443)       -4.25         Net insurance claims incurred       (19,863)       (23,440)       -15.3%       (8,647)       (11,812)       -26.63         Agents, brokers and employee commissions       (1,196)       (1,415)       -15.5%       (551)       (646)       -14.77         Cost of pharma - wholesale       (167,006)       (149,730)       11.5%       (7,740)       73,892       -8.77         Solaries and other employee benefits       (167,006)       (149,730)       11.5%       (7,740)       73,892       -8.77         Salaries and other employee benefits       (49,589)       (47,317)       4.8%       (24,123)       (23,922)       0.87         General and administrative expenses excluding IFRS 16       (33,002)       (30,097)       9.7%       (15,364)       (15,290)       0.53         Impairment of receivables       (3,310)       (2,312)       43.3%       31,565       42,626       -25.95         EBITDA excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,365       -29.66         EBITDA margin excluding IFRS 16       (19,561)       (23,383)       4.9%       (11,864)       (11,715)       1.37      <	Cost of materials and supplies	(26,325)	(24,477)	7.5%	(11,971)	(12,064)	-0.8%
Net insurance claims incurred       (19,863)       (23,440)       -15.3%       (8,647)       (11,812)       -26.88         Agents, brokers and employee commissions       (1,196)       (1,415)       -15.3%       (5,647)       (11,812)       -26.88         Cost of pharma – wholesale       (1,196)       (1,415)       -15.5%       (551)       (646)       -14.77         Cost of pharma – tretail       (167,006)       (14,9730)       11.5%       (75,721)       (76,366)       -0.88         Gross profit       146,833       150,048       -2.1%       67,440       73,892       -8.75         Salaries and other employee benefits       (49,730)       11.5%       (75,721)       (76,366)       -0.08         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.65         Impairment of receivables       (3,310)       (2,312)       43.2%       (1,955)       (1,140)       75.02         BITDA excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,355       -29.66         BITDA margin excluding IFRS 16       13.2%       15.8%       -26,091       8.9%       (14,686)       (13,633)       7.7         Depreciation and amortization	Cost of medical service providers	(1,139)	(1,869)	-39.1%	(374)	(1,070)	-65.0%
Agents, brokers and employee commissions       (1,196)       (1,415)       -15.5%       (551)       (646)       -14.75         Cost of pharma – wholesale       (51,220)       (56,416)       -9.2%       (22,709)       (22,184)       -22.2%         Cost of pharma – retail       (167,006)       (14,97,301)       11.5%       (75,721)       (76,366)       -0.88         Genss profit       146,833       150,048       -2.1%       67,440       73,892       -8.77         Salaries and other employee benefits       (49,589)       (47,317)       4.8%       (24,123)       (22,922)       0.8%         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.6%         Greare land administrative expenses excluding IFRS 16       (33,023)       (30,097)       9.7%       (15,260)       0.55         Impairment of receivables       (1,58       4.454       -62.8%       333       3,826       -91.35         EBITDA excluding IFRS 16       13.2%       15.8%       -2.6ppts       12.3%       15.7%       -3.5ppi         Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.7%         Net interest income (expense)	Cost of utilities and other	(7,739)	(7,780)	-0.5%	(3,300)	(3,443)	-4.2%
Cost of pharma - wholesale       (51,220)       (56,416)       -9.2%       (22,709)       (29,184)       -22.25         Cost of pharma - retail       (167,006)       (149,730)       11.5%       (75,721)       (76,366)       -0.83         Salaries and other employee benefits       (49,589)       (47,317)       4.8%       (24,123)       (23,922)       0.83         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.66         General and administrative expenses excluding IFRS 16       (33,023)       (30,097)       9.7%       (15,364)       (15,290)       0.55         Impairment of receivables       (3,310)       (2,212)       43.2%       (1,995)       (1,140)       75.05         EBITDA       73,889       85,163       -13.3%       31,565       42,626       -25.99         EBITDA margin excluding IFRS 16       13.2%       15.6%       42,626       -25.99       52.96         EBITDA margin excluding IFRS 16       13.2%       15.6%       44,64       -62.8%       33       3,826       -91.3%         Depreciation and amortization       (29,185)       (26,690)       8.9%       (14,686)       (13,633)       7.7%         Net interest income (expens	Net insurance claims incurred	(19,863)	(23,440)	-15.3%	(8,647)	(11,812)	-26.8%
Cost of pharma - retail       (167,006)       (149,730)       11.5%       (75,721)       (76,366)       -0.85         Gross profit       146,833       150,048       -2.1%       67,440       73,892       -8.77         Salaries and other employee benefits       (49,589)       (47,317)       4.8%       (24,123)       (23,922)       0.88         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.66         General and administrative expenses excluding IFRS 16       (33,023)       (30,097)       9.7%       (15,364)       (15,250)       0.53         Impairment of receivables       (3,310)       (2,312)       43.2%       (19,955)       (1,140)       75.00         Other operating income       1,658       4,454       -62.8%       333       3,826       -21.95         EBITDA       62,569       74,776       16.3%       26,221       37,365       -29.65         EBITDA excluding IFRS 16       13.2%       15.8%       -2.6pts       12.3%       15.7%       -3.5ppi         Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.7         Net interest income (expense)       (24,490)	Agents, brokers and employee commissions	(1,196)	(1,415)	-15.5%	(551)	(646)	-14.7%
Gross profit       146,833       150,048       -2.1%       67,440       73,892       -8.75         Salaries and other employee benefits       (49,589)       (47,317)       4.8%       (24,123)       (23,922)       0.86         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,990)       (10,030)       0.66         General and administrative expenses       (21,753)       (19,710)       10.4%       (24,123)       (23,922)       0.85         Impairment of receivables       (3,310)       (2,312)       43.2%       (1,995)       (1,140)       75.00         Other operating income       1,658       4.454       -62.8%       333       3,826       -91.33         EBITDA excluding IFRS 16       73,839       85,163       -13.3%       31,565       42,626       -25.95         EBITDA margin excluding IFRS 16       13.2%       15.8%       -2.6ppts       12.3%       15.7%       -3.5ppt         Depreciation and amortization       (29,185)       (26,809)       8.9%       (11,864)       (11,715)       1.3%         Net interest income (expense)       (21,385)       (20,702)       3.3%       (10,279)       (10,341)       -0.66         Net gains/(losses) from foreign currencies	Cost of pharma – wholesale	(51,220)	(56,416)	-9.2%	(22,709)	(29,184)	-22.2%
Salaries and other employee benefits       (49,589)       (47,317)       4.8%       (24,123)       (23,922)       0.83         General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.66         General and administrative expenses excluding IFRS 16       (33,023)       (30,097)       9.7%       (15,364)       (15,290)       0.53         Impairment of receivables       (3,310)       (2,312)       43.2%       (1,995)       (1,140)       75.00         Other operating income       1,658       4,454       -62.8%       333       3.826       -91.33         EBITDA       73,839       85,163       -13.3%       31,565       42,626       -25.96         EBITDA margin excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,365       -29.66         EBITDA margin excluding IFRS 16       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.77         Depreciation and amortization excluding IFRS 16       (21,385)       (20,702)       3.3%       (10,279)       (10,341)       -0.66         Net gins/(losses) from foreign currencies       (10,424)       (8,955)       15.9%       11,477       (8,846)       NM         N	Cost of pharma - retail	(167,006)	(149,730)	11.5%	(75,721)	(76,366)	-0.8%
General and administrative expenses       (21,753)       (19,710)       10.4%       (10,090)       (10,030)       0.65         General and administrative expenses excluding IFRS 16       (33,023)       (30,097)       9.7%       (15,364)       (15,290)       0.55         Impairment of receivables       (3,310)       (2,312)       43.2%       (1,995)       (1,140)       75.00         Other operating income       1,658       4,454       -62.8%       333       3,826       -91.33         EBITDA excluding IFRS 16       73,839       85,163       -13.3%       31,565       42,626       -25.99         BEITDA margin excluding IFRS 16       13,2%       15,8%       -2,6ppts       12.3%       15,7%       -3,5ppt         Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7,77         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.33%         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net non-recurring income/(expense)       (1,543)       (527)       NMF       (1,567)       (371)       NM         Income tax benef	Gross profit	146,833	150,048	-2.1%	67,440	73,892	-8.7%
General and administrative expenses excluding IFRS 16       (33,023)       (30,097)       9.7%       (15,364)       (15,290)       0.55         Impairment of receivables       (3,310)       (2,312)       43.2%       (1,995)       (1,140)       75.05         Other operating income       1,658       4,454       -62.8%       333       3,826       -91.35         EBITDA       73,839       85,163       -13.3%       31,565       42,626       -25.95         EBITDA margin excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,365       -29,695         Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.7%         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.33         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income (expense)       (1,548)       (357)       NMF       (1,567)       (371)       NM         Profit before in	Salaries and other employee benefits	(49,589)	(47,317)	4.8%	(24,123)	(23,922)	0.8%
Impairment of receivables       (3,310)       (2,312)       43.2%       (1,995)       (1,140)       75.05         Other operating income       1,658       4,454       -62.8%       333       3,826       -91.35         EBITDA       73,839       85,163       -13.3%       31,565       42,626       -25.95         EBITDA excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,365       -29,66         EBITDA margin excluding IFRS 16       13.2%       15.8%       -2.6ppts       12.3%       15.7%       -3.5ppi         Depreciation and amortization excluding IFRS 16       (19,561)       (17,654)       10.8%       (9,844)       (8,975)       9.7%         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.33%         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,333)       (4,244)       50.6%       7,086       (4,388)       NM         Net gains/(losses) from foreign currencies       (1,548)       (357)       NMF       (1,567)       (371)       NM         Profit before income tax	General and administrative expenses	(21,753)	(19,710)	10.4%	(10,090)	(10,030)	0.6%
Impairment of receivables       (3,310)       (2,312)       43.2%       (1,995)       (1,140)       75.05         Other operating income       1,658       4.454       -62.8%       333       3,826       -91.35         EBITDA       73,839       85,163       -13.3%       31,565       42,626       -25.95         EBITDA excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,365       -29,66         EBITDA margin excluding IFRS 16       13.2%       15.8%       -2.6ppts       12.3%       15.7%       -3.5ppt         Depreciation and amortization excluding IFRS 16       (19,961)       (17,654)       10.8%       (9,844)       (8,975)       9.7%         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.33         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,333)       (4,244)       50.6%       7,086       (4,388)       NM         Net gains/(losses) from foreign currencies       (1,548)       (357)       NMF       (1,567)       (371)       NMF         Income tax benefit/(expen	General and administrative expenses excluding IFRS 16	(33,023)	(30,097)	9.7%	(15,364)	(15,290)	0.5%
Other operating income       1,658       4,454       -62.8%       333       3,826       -91.35         EBITDA       73,839       85,163       -13.3%       31,565       42,626       -25.95         EBITDA margin excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,365       -2.965         Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.75         Depreciation and amortization excluding IFRS 16       (19,561)       (17,754)       10.8%       (9,844)       (8,975)       9.77         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.35         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net operiadition tax expense       74,06       25,479       -70.9%       14,925       8,062       85.11         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.35         Income tax benefit/(expense) <td>Impairment of receivables</td> <td></td> <td></td> <td>43.2%</td> <td></td> <td></td> <td>75.0%</td>	Impairment of receivables			43.2%			75.0%
EBITDA       73,839       85,163       -13.3%       31,565       42,626       -25.99         EBITDA excluding IFRS 16       62,569       74,776       -16.3%       26,291       37,365       -29,65         EBITDA margin excluding IFRS 16       13.2%       15.8%       -2.6ppts       12.3%       15.7%       -3.5ppt         Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.7%         Depreciation and amortization excluding IFRS 16       (19,561)       (17,654)       10.8%       (9,844)       (8,975)       9.7%         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.33         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net ono-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NM         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       86.519         Income tax ben				-62.8%			-91.3%
EBITDA margin excluding IFRS 16       13.2%       15.8%       -2.6ppts       12.3%       15.7%       -3.5ppt         Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.7         Depreciation and amortization excluding IFRS 16       (19,561)       (17,654)       10.8%       (9,844)       (8,975)       9.75         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.3.3%         Net interest income (expense) excluding IFRS 16       (21,385)       (20,702)       3.3%       (10,279)       (10,341)       -0.65         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1567)       (371)       NM         Income tax benefit/(expense)       7,406       25,479       -70.9%       14,925       8,062       85.17         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.33         Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.57 <t< td=""><td>EBITDA</td><td>73,839</td><td>85,163</td><td>-13.3%</td><td>31,565</td><td>42,626</td><td>-25.9%</td></t<>	EBITDA	73,839	85,163	-13.3%	31,565	42,626	-25.9%
Depreciation and amortization       (29,185)       (26,809)       8.9%       (14,686)       (13,633)       7.75         Depreciation and amortization excluding IFRS 16       (19,561)       (17,654)       10.8%       (9,844)       (8,975)       9.77         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.35         Net interest income (expense)       (21,385)       (20,702)       3.3%       (10,279)       (10,341)       -0.66         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NM         Income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.17         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.35         Income tax benefit/expenses       7,790       9,551       -18.4%       6,795       3,534       92.35         Profit bere	EBITDA excluding IFRS 16	62,569	74,776	-16.3%	26,291	37,365	-29.6%
Depreciation and amortization excluding IFRS 16       (19,561)       (17,654)       10.8%       (9,844)       (8,975)       9.75         Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.35         Net gins/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net non-recurring income/(expense)       (23,333)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (23,34)       (527)       NMF       (1,567)       (371)       NM         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.19         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.35         Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.55         Attributable to:       - <td>EBITDA margin excluding IFRS 16</td> <td>13.2%</td> <td>15.8%</td> <td>-2.6ppts</td> <td>12.3%</td> <td>15.7%</td> <td>-3.5ppts</td>	EBITDA margin excluding IFRS 16	13.2%	15.8%	-2.6ppts	12.3%	15.7%	-3.5ppts
Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.39         Net interest income (expense)       excluding IFRS 16       (21,385)       (20,702)       3.3%       (10,279)       (10,341)       -0.66         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NMF         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.19         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.33         Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.59         Attributable to:       -       -       -       -       -       -       -       -       81.79       -       -       -       -       -       -       -       -       -       -       -       -	Depreciation and amortization	(29,185)	(26,809)	8.9%	(14,686)	(13,633)	7.7%
Net interest income (expense)       (24,490)       (23,353)       4.9%       (11,864)       (11,715)       1.39         Net interest income (expense)       excluding IFRS 16       (21,385)       (20,702)       3.3%       (10,279)       (10,341)       -0.66         Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NMF         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.19         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.33         Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.59         Attributable to:       -       -       -       -       -       -       -       -       81.79       -       -       -       -       -       -       -       -       -       -       -       -	Depreciation and amortization excluding IFRS 16	(19,561)	(17,654)	10.8%	(9,844)	(8,975)	9.7%
Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NM         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.11         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.35         Profit before income tax expense       5,858       25,122       -76.7%       14,527       7,790       86.55         Attributable to:       -	Net interest income (expense)	(24,490)	(23,353)	4.9%	(11,864)	(11,715)	1.3%
Net gains/(losses) from foreign currencies       (10,424)       (8,995)       15.9%       11,477       (8,846)       NM         Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NM         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.11         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.35         Profit before income tax expense       5,858       25,122       -76.7%       14,527       7,790       86.55         Attributable to:       -	Net interest income (expense) excluding IFRS 16	(21,385)	(20,702)	3.3%	(10,279)	(10,341)	-0.6%
Net gains/(losses) from foreign currencies excluding IFRS 16       (6,393)       (4,244)       50.6%       7,086       (4,388)       NM         Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NM         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.19         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.35         Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.55         Attributable to:       -		(10,424)	(8,995)	15.9%	11,477	(8,846)	NMF
Net non-recurring income/(expense)       (2,334)       (527)       NMF       (1,567)       (371)       NM         Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.19         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.35         Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.59         Attributable to:       -       -       -       -       -       -       8.62       81.79         - shareholders of the Company       (1,932)       15,571       NMF       7,732       4,256       81.79         - non-controlling interests       7,790       9,551       -18.4%       6,795       3,534       92.39         Profit for the period excluding IFRS 16       11,348       31,292       -63.7%       11,289       13,019       -13.39         Attributable to:       -       -       shareholders of the Company       2,079       20,278       -89.7%       5,443       8,281       -34.39		(6,393)	(4,244)	50.6%	7,086	(4,388)	NMF
Profit before income tax expense       7,406       25,479       -70.9%       14,925       8,062       85.19         Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.33         Profit for the period       5,858       25,122       -76.7%       14,925       8,062       85.19         Attributable to:       -       -       -       -       -       -         - shareholders of the Company       (1,932)       15,571       NMF       7,732       4,256       81.79         - non-controlling interests       7,790       9,551       -18.4%       6,795       3,534       92.33         Profit for the period excluding IFRS 16       11,348       31,292       -63.7%       11,289       13,019       -13.39         Attributable to:       -       -       shareholders of the Company       2,079       20,278       -89.7%       5,443       8,281       -34.39		(2,334)	(527)	NMF	(1,567)	(371)	NMF
Income tax benefit/(expense)       (1,548)       (357)       NMF       (398)       (272)       46.33         Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.55         Attributable to:       -       -       11,932)       15,571       NMF       7,732       4,256       81.77         - non-controlling interests       7,790       9,551       -18.4%       6,795       3,534       92.33         Profit for the period excluding IFRS 16       11,348       31,292       -63.7%       11,289       13,019       -13.39         Attributable to:       -       -       shareholders of the Company       2,079       20,278       -89.7%       5,443       8,281       -34.39				-70.9%			85.1%
Profit for the period       5,858       25,122       -76.7%       14,527       7,790       86.59         Attributable to:       - shareholders of the Company       (1,932)       15,571       NMF       7,732       4,256       81.79         - non-controlling interests       7,790       9,551       -18.4%       6,795       3,534       92.39         Profit for the period excluding IFRS 16       11,348       31,292       -63.7%       11,289       13,019       -13.39         Attributable to:       - shareholders of the Company       2,079       20,278       -89.7%       5,443       8,281       -34.39				NMF			46.3%
Attributable to:       - shareholders of the Company       (1,932)       15,571       NMF       7,732       4,256       81.79         - non-controlling interests       7,790       9,551       -18.4%       6,795       3,534       92.35         Profit for the period excluding IFRS 16       11,348       31,292       -63.7%       11,289       13,019       -13.35         Attributable to:       - shareholders of the Company       2,079       20,278       -89.7%       5,443       8,281       -34.35		5.858	25,122	-76.7%	14,527	7,790	86.5%
- non-controlling interests       7,790       9,551       -18.4%       6,795       3,534       92.33         Profit for the period excluding IFRS 16       11,348       31,292       -63.7%       11,289       13,019       -13.33         Attributable to:       - shareholders of the Company       2,079       20,278       -89.7%       5,443       8,281       -34.33	Attributable to:					•	
- non-controlling interests       7,790       9,551       -18.4%       6,795       3,534       92.33         Profit for the period excluding IFRS 16       11,348       31,292       -63.7%       11,289       13,019       -13.33         Attributable to:       - shareholders of the Company       2,079       20,278       -89.7%       5,443       8,281       -34.33		(1.932)	15,571	NMF	7,732	4,256	81.7%
Attributable to:         2,079         20,278         -89.7%         5,443         8,281         -34.39							92.3%
	Profit for the period excluding IFRS 16 Attributable to:	11,348	31,292	-63.7%	11,289	13,019	-13.3%
	- shareholders of the Company	2,079	20,278	-89.7%	5,443	8,281	-34.3%
	- non-controlling interests	9,269	11,014	-15.8%	5,846	4,738	23.4%

Page 107

### **GHG Consolidated financial highlights (cont'd)**



Statement of	Balance sheet											
GEL thousands, unless otherwise noted	1H20	1H19	Change	2Q20	2Q19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	Change	Jun-19	Change
Cash flows from / (used in) operating activities			5			5	Total assets, of which:	1,428,717	1,351,207	5.7%	1,329,411	7.5%
Revenue received	499,674	451,829	10.6%	239,602	233,963	2.4%	Cash and bank deposits	120,039	32,005	NMF	27,207	NMF
Cost of services paid	(321,039)	(318,412)	0.8%	(146,883)	(163,308)	-10.1%	Receivables from healthcare services	99,183	130,212	-23.8%	124,050	-20.0%
Gross profit received	178,635	133,417	33.9%	92,718	70,655	31.2%	Receivables from sale of pharmaceuticals	16,951	17,508	-3.2%	18,808	-9.9%
Salaries paid	(52,825)	(47,439)	11.4%	(30,287)	(25,263)	19.9%	Insurance premiums receivable	34,675	26,892	28.9%	44,737	-22.5%
General and administrative expenses paid	(22,294)	(20,432)	9.1%	(9,425)	(10,297)	-8.5%	Property and equipment	663,405	671,658	-1.2%	672,785	-1.4%
General and administrative expenses paid, excluding IFRS 16	(33,564)	(30,984)	8.3%	(14,699)	(15,881)	-7.4%	Right of use assets	77,764	84,115	-7.6%	79,908	-2.7%
Other operating income/(expense) and tax paid	(612)	370	NMF	(458)	(468)	-2.1%	Goodwill and other intangible assets	165,786	162,247	2.2%	156,042	6.2%
Net cash flows from operating activities before income tax	102,904	65,916	<b>56.1%</b>	52,548	34,627	51.8%	Inventory	188.606	174,462	8.1%	150,042	20.0%
Income tax paid	(1,636)	(194)	NMF	(469)	(108)	NMF	5	16,122	12,289	31.2%	14,156	13.9%
Net cash flows from operating activities	101,268	65,722	54.1%	52,079	34,519	<b>50.9%</b>	Prepayments Other assets	46,186	39,819	51.2% 16.0%	34,586	33.5%
Net cash flows from operating activities, excluding IFRS 16	89,998	55,170	63.1%	46,805	28,935	61.8%			39,819		34,586	33.5% NMF
							Of which, securities	4,431	-	NMF	-	
Cash flows from / (used in) investing activities							Total liabilities, of which:	835,192	748,933	11.5%	757,709	10.2%
Cash outflow on Capex	(16,245)	(20,665)	-21.4%	(6,502)	(11,160)	-41.7%	Borrowed Funds	414,540	363,585	14.0%	368,895	12.4%
Acquisition of subsidiaries/payments of holdback	(5,445)	(6,101)	-10.8%	-	(877)	NMF	Accounts payable	144,975	128,700	12.6%	119,784	21.0%
Interest income received	1,675	1,243	34.8%	1,259	917	37.3%	Insurance contract liabilities	33,704	25,489	32.2%	43,160	-21.9%
Other investing activities	1,034	3,516	-70.6%	860	3,249	-73.5%	Finance lease liabilities, of which:	89,739	90,791	-1.2%	85,942	4.4%
Net cash flow used in investing activities	(18,981)	(22,007)	-13.8%	(4,383)	(7,871)	-44.3%	IFRS 16 impact	81,063	82,115	-1.3%	77,266	4.9%
							Other liabilities	152,234	140,368	8.5%	139,928	8.8%
Cash flows from / (used in) financing activities							Total shareholders' equity attributable to:	593,525	602,274	-1.5%	571,702	3.8%
Payment of dividends to minorities	(6,036)	(4,950)	21.9%	(2,316)	(1,980)	17.0%	Shareholders of the Company	521,702	530,899	-1.7%	502,640	3.8%
Purchase of treasury shares	(1,452)	(1,582)	-8.2%	(1,452)	(1,272)	14.2%	Non-controlling interest	71,823	71,375	0.6%	69,062	4.0%
Payment of finance lease liabilities	(8,165)	(7,949)	2.7%	(3,689)	(4,248)	-13.2%						
Interest expense paid on finance lease	(3,105)	(2,603)	19.3%	(1,585)	(1,336)	18.6%						
Increase/(decrease) in borrowings	32,633	(29,094)	NMF	16,602	(8,083)	NMF						
Interest expense paid	(10,271)	(18,297)	-43.9%	(3,175)	(10,192)	-68.9%						
Net cash flows (used in)/from financing activities	3,604	(64,475)	NMF	4,385	(27,111)	NMF						
Net cash flows (used in)/from financing activities, excluding IFRS 16	14,874	(53,923)	NMF	9,659	(21,527)	NMF						
Effect of exchange rates changes on cash and cash equivalents	2,142	6	NMF	(205)	74	NMF						
Net increase/(decrease) in cash and cash equivalents	88,033	(20,754)	NMF	51,875	(388)	NMF						
Cash and bank deposits, beginning	32,005	47,961	-33.3%	68,163	27,595	147.0%						
Cash and bank deposits, ending	120,039	27,207	NMF	120,039	27,207	NMF						

### Healthcare services business financial highlights (cont'd)



Income statement														
		Hospitals		CI	inics		D	agnostics		Eliminati	ons		Total	
GEL thousands, unless otherwise noted	1H20	1H19	Change	1H20	1H19	Change	1H20	1H19	Change	1H20	1H19	1H20	1H19	Change
Revenue, gross	126,720	148,992	-14.9%	21,461	21,984	-2.4%	3,447	2,285	50.9%	(3,211)	(2,143)	148,417	171,118	-13.3%
Corrections & rebates	(1,370)	(994)	37.8%	(223)	(170)	31.2%	_	-	-		-	(1,593)	(1,164)	36.9%
Revenue, net	125,350	147,998	-15.3%	21,238	21,814	-2.6%	3,447	2,285	<b>50.9%</b>	(3,211)	(2,143)	146,824	169,954	-13.6%
Costs of services	(79,250)	(85,661)	-7.5%	(11,865)	(12,467)	-4.8%	(3,090)	(1,605)	92.5%	3,213	1,810	(90,992)	(97,923)	-7.1%
Cost of salaries and other employee benefits	(45,367)	(51,430)	-11.8%	(7,306)	(7,632)	-4.3%	(770)	(549)	40.3%	-	-	(53,443)	(59,611)	-10.3%
Cost of materials and supplies	(24,793)	(25,300)	-2.0%	(1,397)	(1,398)	-0.1%	(2,051)	(821)	NMF	-	(329)	(28,241)	(27,848)	1.4%
Cost of medical service providers	(2,429)	(2,107)	15.3%	(1,788)	(2,247)	-20.4%	(50)	(46)	8.7%	2,981	2,133	(1,286)	(2,267)	-43.3%
Cost of utilities and other	(6,661)	(6,824)	-2.4%	(1,374)	(1,190)	15.5%	(219)	(189)	15.9%	232	6	(8,022)	(8,197)	-2.1%
Gross profit	46,100	62,337	-26.0%	9,373	9,347	0.3%	357	680	-47.5%	2	(333)	55,832	72,031	-22.5%
Salaries and other employee benefits	(16,606)	(16,109)	3.1%	(3,925)	(3,539)	10.9%	(454)	(515)	-11.8%	-	-	(20,985)	(20,163)	4.1%
General and administrative expenses	(6,192)	(6,989)	-11.4%	(1,654)	(1,419)	16.6%	(122)	(149)	-18.1%	25	(51)	(7,943)	(8,608)	-7.7%
G&A excl. IFRS 16	(6,371)	(7,288)	-12.6%	(2,232)	(2,174)	2.7%	(122)	(160)	-23.8%	25	(51)	(8,700)	(9,673)	-10.1%
Impairment of receivables	(2,137)	(2,265)	-5.7%	(55)	(90)	-38.9%	-	(4)	NMF	-		(2,192)	(2,359)	-7.1%
Other operating income	1,470	1,327	10.8%	445	439	1.4%	100	96	4.2%	(52)	404	1,963	2,266	-13.4%
EBITDA	22,635	38,301	-40.9%	4,184	4,738	-11.7%	(119)	108	NMF	(25)	20	26,675	43,167	-38.2%
EBITDA excluding IFRS 16	22,456	38,002	-40.9%	3,606	3,983	-9.5%	(119)	97	NMF	(25)	20	25,918	42,102	-38.4%
EBITDA margin excluding IFRS 16	17.7%	25.5%	-7.8ppts	16.8%	18.1%	-1.3ppts	-3.5%	4.2%	-7.7ppts			17.5%	24.6%	-7.1ppts
Depreciation and amortization	(14,763)	(13,599)	8.6%	(3,558)	(3,290)	8.1%	(63)	(132)	-52.3%	-	-	(18,384)	(17,021)	8.0%
Depreciation and amortization excl. IFRS 16	(14,384)	(13,244)	8.6%	(2,834)	(2,485)	14.0%	(63)	(119)	-47.1%	-	-	(17,281)	(15,848)	9.0%
Net interest income (expense)	(14,060)	(13,233)	6.2%	(2,594)	(2,212)	17.3%	(233)	(1)	NMF	-	-	(16,887)	(15,446)	9.3%
Net interest income (expense) excl. IFRS 16	(13,975)	(13,168)	6.1%	(2,331)	(1,955)	19.2%	(233)	-	NMF	-	-	(16,539)	(15,123)	9.4%
Net gains/(losses) from foreign currencies	(1,924)	(1,552)	24.0%	(176)	(895)	-80.3%	(3)	(20)	-85.0%	-	-	(2,103)	(2,467)	-14.8%
Net gains/(losses) from FX excl. IFRS 16	(1,848)	(1,145)	61.4%	16	(62)	NMF	(3)	(20)	-85.0%	-	-	(1,835)	(1,227)	49.6%
Net non-recurring income/(expense)	(2,007)	(392)	NMF	(97)	(67)	44.8%	-	(5)	NMF	-	-	(2,104)	(464)	NMF
Profit before income tax expense	(10,119)	9,525	NMF	(2,241)	(1,726)	-29.8%	(418)	(50)	NMF	(25)	20	(12,803)	7,769	NMF
Profit for the period	(10,119)	9,525	NMF	(2,241)	(1,726)	-29.8%	(418)	(50)	NMF	(25)	20	(12,803)	7,769	NMF
Attributable to:														
- shareholders of the Company	(10,521)	6,754	NMF	(2,288)	(1,760)	-30.0%	(418)	(50)	NMF	(25)	20	(13,252)	4,964	NMF
- non-controlling interests	402	2,771	-85.5%	47	34	38.2%	-	-	-	-	-	449	2,805	-84.0%
Profit for the period excluding IFRS 16 Attributable to:	(9,758)	10,053	NMF	(1,640)	(586)	NMF	(418)	(47)	NMF	(25)	20	(11,841)	9,440	NMF
- shareholders of the Company	(10,160)	7,282	NMF	(1,687)	(620)	NMF	(418)	(47)	NMF	(25)	20	(12,290)	6,635	NMF
- non-controlling interests	402	2,771	-85.5%	47	34	38.2%	-	-	NMF	-	-	449	2,805	-84.0%

# Healthcare services business financial highlights (cont'd)



Income statement														
		Hospitals		Cli	inics		Di	agnostics		Eliminatio	ons		Total	
GEL thousands, unless otherwise noted	2Q20	2Q19	Change	2Q20	2Q19	Change	2Q20	2Q19	Change	2Q20	2Q19	2Q20	2Q19	Change
Revenue, gross	55,901	74,218	-24.7%	9,321	10,877	-14.3%	1,781	1,131	57.5%	(1,523)	(906)	65,480	85,320	-23.3%
Corrections & rebates	(521)	(532)	-2.1%	(115)	(73)	57.5%	-	-	-	-	-	(636)	(605)	5.1%
Revenue, net	55,380	73,686	-24.8%	9,206	10,804	-14.8%	1,781	1,131	57.5%	(1,523)	(906)	64,844	84,715	-23.5%
Costs of services	(35,502)	(42,640)	-16.7%	(5,093)	(6,223)	-18.2%	(1,476)	(774)	90.7%	1,555	573	(40,516)	(49,064)	-17.4%
Cost of salaries and other employee benefits	(20,285)	(26,189)	-22.5%	(3,195)	(3,789)	-15.7%	(367)	(260)	41.2%	-	-	(23,847)	(30,238)	-21.1%
Cost of materials and supplies	(11,198)	(12,281)	-8.8%	(650)	(721)	-9.8%	(983)	(428)	NMF	-	(329)	(12,831)	(13,759)	-6.7%
Cost of medical service providers	(1,066)	(1,095)	-2.6%	(780)	(1,183)	-34.1%	(40)	(45)	-11.1%	1,454	896	(432)	(1,427)	-69.7%
Cost of utilities and other	(2,953)	(3,075)	-4.0%	(468)	(530)	-11.7%	(86)	(41)	NMF	101	6	(3,406)	(3,640)	-6.4%
Gross profit	19,878	31,046	-36.0%	4,113	4,581	-10.2%	305	357	-14.6%	32	(333)	24,328	35,651	-31.8%
Salaries and other employee benefits	(8,316)	(8,157)	2.0%	(1,963)	(1,783)	10.1%	(295)	(281)	5.1%		-	(10,574)	(10,220)	3.5%
General and administrative expenses	(3,149)	(3,741)	-15.8%	(719)	(791)	-9.1%	(30)	(71)	-57.7%	7	(51)	(3,891)	(4,654)	-16.4%
G&A excl. IFRS 16	(3,203)	(3,861)	-17.0%	(981)	(1,092)	-10.2%	(30)	(76)	-60.6%	7	(51)	(4,207)	(5,080)	-17.2%
Impairment of receivables	(984)	(1,128)	-12.8%	(35)	(15)	NMF	-	-	NMF	-	-	(1,019)	(1,143)	-10.8%
Other operating income	333	940	-64.6%	87	216	-59.7%	47	49	-4.1%	(18)	404	449	1,609	-72.1%
EBITDA	7,762	18,960	-59.1%	1,483	2,208	-32.8%	27	54	-50.3%	21	20	9,293	21,243	-56.3%
EBITDA excluding IFRS 16	7,708	18,840	-59.1%	1,221	1,907	-36.0%	27	49	-45.0%	21	20	8,977	20,816	-56.9%
EBITDA margin excluding IFRS 16	13.8%	25.4%	-11.6ppts	13.1%	17.5%	-4.4ppts	1.5%	4.3%	-2.8ppts	-	-	13.7%	24.4%	-10.7ppts
Depreciation and amortization	(7,433)	(6,920)	7.4%	(1,771)	(1,664)	6.4%	(34)	(67)	-49.3%	-	-	(9,238)	(8,652)	6.8%
Depreciation and amortization excl. IFRS 16	(7,232)	(6,728)	7.5%	(1,409)	(1,257)	12.1%	(34)	(60)	-43.4%	-	-	(8,675)	(8,046)	7.8%
Net interest income (expense)	(6,767)	(6,620)	2.2%	(1,294)	(1,126)	14.9%	(118)	(1)	NMF	-	-	(8,179)	(7,747)	5.6%
Net interest income (expense) excl. IFRS 16	(6,720)	(6,586)	2.0%	(1,155)	(998)	15.7%	(118)	-	NMF	-	-	(7,993)	(7,584)	5.4%
Net gains/(losses) from foreign currencies	2,327	(1,437)	NMF	649	(834)	NMF	-	(14)	NMF	-	-	2,976	(2,286)	NMF
Net gains/(losses) from FX excl. IFRS 16	2,219	(1,052)	NMF	(9)	(35)	-74.4%	-	(14)	NMF	-	-	2,210	(1,102)	NMF
Net non-recurring income/(expense)	(1,374)	(288)	NMF	(20)	(15)	33.3%	-	-	NMF	-	-	(1,394)	(303)	NMF
Profit before income tax expense	(5,485)	3,696	NMF	(953)	(1,432)	-33.4%	(125)	(28)	NMF	21	20	(6,542)	2,256	NMF
Profit for the period	(5,485)	3,696	NMF	(953)	(1,432)	-33.4%	(125)	(28)	NMF	21	20	(6,542)	2,256	NMF
Attributable to:														
- shareholders of the Company	(5,480)	2,437	NMF	(961)	(1,446)	-33.5%	(125)	(28)	NMF	21	20	(6,545)	983	NMF
- non-controlling interests	(5)	1,259	NMF	8	14	-42.9%	-	-	NMF	-	-	3	1,273	-99.8%
Profit for the period excluding IFRS 16 Attributable to:	(5,399)	4,186	NMF	(1,372)	(398)	NMF	(125)	(26)	NMF	21	20	(6,875)	3,782	NMF
- shareholders of the Company	(5,394)	2,927	NMF	(1,380)	(412)	NMF	(125)	(26)	NMF	21	20	(6,878)	2,509	NMF
- non-controlling interests	(5)	1,259	NMF	8	14	-42.9%	-	-	NMF	-	-	3	1,273	-99.8%

### Healthcare services business financial highlights (cont'd)



Change

**3.4%** NMF -17.9% -2.1% -1.6%

9.7% 2.5%

41.5%

52.2%

NMF **7.7%** 

5.1% 24.0% 8.9%

**-0.9%** -1.7%

4.0%

Statement of	cash fl	ow					Bala	nce she	et		
GEL thousands, unless otherwise noted	1H20	1H19	Change	2Q20	2Q19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	Change	Jun-19
Cash flows from / (used in) operating activities			5		-	5	Total assets, of which:	960,076	953,874	0.7%	928,668
Revenue received	175,530	160,951	9.1%	84,663	79,494	6.5%	Cash and bank deposits	41,958	7,648	NMF	3,277
Cost of services paid	(87,266)	(112,120)	-22.2%	(45,754)	(56,038)	-18.4%	Receivables from healthcare services	108,671	140,861	-22.9%	132,284
Gross profit received	88,264	48,831	80.8%	38,909	23,455	65.9%	Property and equipment	613,727	621,443	-1.2%	627,024
Salaries paid	(22,520)	(18,534)	21.5%	(13,015)	(8,386)	55.2%	Right of use assets	10,064	11,369	-11.5%	10,226
General and administrative expenses paid	(10,832)	(8,001)	35.4%	(4,365)	(4,036)	8.1%	Goodwill and other intangible assets	107,772	104,222	3.4% -3.2%	98,224
General and administrative expenses paid, excluding IFRS 16	(11,589)	(9,069)	27.8%	(4,681)	(4,623)	1.2%	Inventory Prepayments	18,771 9,724	19,387 7,937	-3.2% 22.5%	18,319 6,873
Other operating income/(expense) and tax paid	(499)	59	NMF	(445)	(1,252)	-64.4%	Other assets	49,389	41,007	20.4%	32,440
Net cash flows from operating activities before income tax	54,413	22,355	143.4%	21,084	9,781	115.6%	Of which, securities and intercompany loans	3,618	41,007	20.478 NMF	52,440
Income tax paid	(43)	(129)	-66.7%	(43)	(109)	-60.4%	Total liabilities, of which:	495,606	472,675	4.9%	460.148
Net cash flows from operating activities	54,370	22,226	144.6%	21,041	9,673	117.5%	Borrowed Funds	304,060	291,239	4.4%	289,368
Net cash flows from operating activities, excluding IFRS 16	53,613	21,158	153.4%	20,725	9,086	128.1%	Accounts payable	46,004	45,754	0.5%	37,087
							Other liabilities	145,542	135,682	7.3%	133,692
Cash flows from / (used in) investing activities							Total shareholders' equity attributable to:	464,470	481,199	-3.5%	468,521
Cash outflow on Capex	(13,689)	(17,383)	-21.3%	(5,472)	(9,345)	-41.4%	Shareholders of the Company	392,247	409,424	-4.2%	399,059
Acquisition of subsidiaries/payments of holdback	(5,445)	(6,101)	-10.8%	-	(877)	NMF	Non-controlling interest	72,223	71,775	0.6%	69,462
Interest income received	142	532	-73.3%	95	472	-79.9%					
Dividends and intersegment loans issued/received	(1,286)	12,103	NMF	(8,444)	6,273	NMF					
Net cash flow used in investing activities	(20,278)	(10,849)	86.9%	(13,821)	(3,477)	NMF					
Cash (lawa farma / (and in) firms in a sticities											
Cash flows from / (used in) financing activities Purchase of treasury shares	(1.024)	(1,194)	-14.2%	(1,024)	(004)	15.8%					
Payment of finance lease liabilities	(1,024) (409)	(1,194) (745)	-14.2%	(1,024)	(884) (424)	-69.3%					
Interest expense paid on finance lease	(409)	(745)	-45.1%	(130)	(424)	13.9%					
Increase/(decrease) in borrowings	(546) 10,447	. ,	7.7% NMF	. ,	(103)	NMF					
		(7,510)		16,847 (2,200)	(9,384)	-76.6%					
Interest expense paid	(8,856)	(16,475) ( <b>26,247)</b>	-46.2%		,	-76.6% NMF					
Net cash flows (used in)/from financing activities	(190)	,	-99.3%	13,307 13,623	(11,032)	NMF					
Net cash flows (used in)/from financing activities, excluding IFRS 16	567	(25,179)	NMF	13,023	(10,446)	NIVIF					
Effect of exchange rates changes on cash and cash equivalents	408	(146)	NMF	198	(91)	NMF					
Net increase/(decrease) in cash and cash equivalents	34,310	(15,016)	NMF	20,725	(4,928)	NMF					
Cash and bank deposits, beginning	7,648	18,293	-58.2%	21,233	8,205	158.8%					
Cash and bank deposits, ending	41,958	3,277	NMF	41,958	3,277	NMF					

# Pharmacy and distribution business financial highlights



Income statement           GEL thousands, unless otherwise noted         1H20         1H19         Change         2Q20         2Q19         Change														
GEL thousands, unless otherwise noted	1H20	1H19	Change	2Q20	2Q19	Change								
Revenue	318,840	295,193	8.0%	143,811	149,414	-3.7%								
Costs of services	(235,122)	(220,944)	6.4%	(105,378)	(113,463)	-7.1%								
Cost of pharma – wholesale	(68,116)	(71,214)	-4.4%	(29,657)	(37,097)	-20.1%								
Cost of pharma - retail	(167,006)	(149,730)	11.5%	(75,721)	(76,366)	-0.8%								
Gross profit	83,718	74,249	12.8%	38,433	35,951	6.9%								
Salaries and other employee benefits	(27,324)	(25,244)	8.2%	(12,545)	(12,580)	-0.3%								
General and administrative expenses	(12,264)	(10,653)	15.1%	(5,685)	(5,146)	10.5%								
General and administrative expenses excluding IFRS 16	(22,574)	(19,794)	14.0%	(10,550)	(9,885)	6.7%								
Impairment of receivables	(343)	(179)	91.6%	(342)	(121)	NMF								
Other operating income	151	1,876	-92.0%	46	1,982	-97.7%								
EBITDA	43,938	40,049	9.7%	19,907	20,086	-0.9%								
EBITDA excluding IFRS 16	33,628	30,908	8.8%	15,042	15,347	-2.0%								
EBITDA margin excluding IFRS 16	10.5%	10.5%	NMF	10.5%	10.3%	0.2ppts								
Depreciation and amortization	(10,226)	(9,240)	10.7%	(5,153)	(4,702)	9.6%								
Depreciation and amortization excluding IFRS 16	(1,887)	(1,426)	32.3%	(964)	(738)	30.6%								
Net interest income (expense)	(8,367)	(8,193)	2.1%	(4,088)	(4,141)	-1.3%								
Net interest income (expense) excluding IFRS 16	(5,639)	(5,892)	-4.3%	(2,703)	(2,943)	-8.2%								
Net gains/(losses) from foreign currencies	(8,289)	(6,546)	26.6%	8,460	(6,519)	NMF								
Net gains/(losses) from foreign currencies excluding IFRS 16	(4,566)	(3,088)	47.9%	4,874	(3,294)	NMF								
Net non-recurring income/(expense)	(72)	(62)	16.1%	(15)	(68)	-77.9%								
Profit before income tax expense	16,984	16,008	6.1%	19,111	4,656	NMF								
Income tax benefit/(expense)	(945)	(69)	NMF	-	(69)	NMF								
Profit for the period	16,039	15,939	0.6%	19,111	4,587	NMF								
Attributable to:														
- shareholders of the Company	8,698	9,193	-5.4%	12,319	2,326	NMF								
- non-controlling interests	7,341	6,746	8.8%	6,792	2,261	NMF								
Profit for the period excluding IFRS 16	20,519	20,371	0.7%	16,234	8,235	97.1%								
Attributable to:														
- shareholders of the Company	11,699	12,162	-3.8%	10,391	4,770	NMF								
-non-controlling interests	8,820	8,209	7.4%	5,843	3,465	68.6%								

#### Pharmacy and distribution business financial highlights (cont'd) (D) GEORGIA CAPITAL

Statement of	cash flo	w		Bala	nce she	et						
GEL thousands, unless otherwise noted	1H20	1H19	Change	2Q20	2Q19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	Change	Jun-19	Change
Cash flows from / (used in) operating activities							Total assets, of which:	454,006	396,078	14.6%	359,342	26.3%
Revenue received	312,119	279,962	11.5%	148,374	147,100	0.9%	Cash and bank deposits	56,797	7,774	NMF	9,702	NMF
Cost of services paid	(231,608)	(203,598)	13.8%	(100,025)	(105,623)	-5.3%	Receivables from sale of pharmaceuticals	43,099	40,157	7.3%	33,820	27.4%
Gross profit received	80,511	76,364	5.4%	48,349	41,476	16.6%	Property and equipment	34,788	35,161	-1.1%	30,604	13.7%
Salaries paid	(25,482)	(24,516)	3.9%	(14,216)	(13,992)	1.6%	Right of use assets	67,097	72,149	-7.0%	68,902	-2.6%
General and administrative expenses paid	(10,386)	(11,588)	-10.4%	(4,693)	(5,770)	-18.7%	Goodwill and other intangible assets	52,620	52,506	0.2%	52,329	0.6%
General and administrative expenses paid, excluding IFRS 16	(20,696)	(20,891)	-0.9%	(9,558)	(10,671)	-10.4%	Inventory	169,637	155,075	9.4%	138,813	22.2%
Other operating income/(expense) and tax paid	(494)	-	NMF	(75)	635	NMF	Prepayments	5,296	3,832	38.2%	6,578	-19.5%
Net cash flows from operating activities before income tax	44,149	40,260	9.7%	29,365	22,349	31.4%	Other assets	24,672	29,424	-16.2%	18,593	32.7%
Income tax paid	(463)	(65)	NMF	(196)	-	NMF	Of which, securities and intercompany loans	12,327	12,167	1.3%	2,495	NMF
Net cash flows from operating activities	43,686	40,195	8.7%	29,169	22,349	30.5%	Total liabilities, of which:	355,204	303,240	17.1%	284,416	24.9%
Net cash flows from operating activities, excluding IFRS 16	33,376	30,892	8.0%	24,304	17,449	39.3%	Borrowed Funds	120,751	84,712	42.5%	79,489	51.9%
							Accounts payable	129,343	110,690	16.9%	100,349	28.9%
Cash flows from /(used in) investing activities							Other liabilities	105,110	107,838	-2.5%	104,579	0.5%
Cash outflow on Capex	(2,384)	(3,253)	-26.7%	(933)	(1,815)	-48.6%	Total shareholders' equity	98,802	92,838	6.4%	74,925	31.9%
Interest income received	1,120	13	NMF	851	5	NMF						
Intersegment loans issued proceeds from other investing activities	846	3,000	-71.8%	8	6,526	-99.9%						
Net cash flow used in investing activities	(418)	(240)	74.2%	(74)	4,716	NMF						
Cash flows from / (used in) financing activities	(10.000)	(15.000)	05.00/	(7.0.44)	(6.000)							
Payment of dividends	(18,833)	(15,000)	25.6%	(7,341)	(6,000)	22.4%						
Purchase of treasury shares	(273)	(245)	11.4%	(273)	(245)	11.4%						
Payment of finance lease liabilities	(7,582)	(7,050)	7.5%	(3,480)	(3,750)	-7.2%						
Interest expense paid on finance lease	(2,728)	(2,253)	21.1%	(1,385)	(1,150)	20.4%						
Increase/(decrease) in borrowings	35,910	(21,514)	NMF	15,078	(12,836)	NMF						
Interest expense paid	(2,031)	(1,645)	23.5%	(1,263)	(811)	55.6%						
Net cash flows (used in)/from financing activities	4,463	(47,707)	NMF	1,336	(24,793)	NMF						
Net cash flows (used in)/from financing activities, excluding IFRS 16	14,773	(38,404)	NMF	6,201	(19,893)	NMF						
Effect of exchange rates changes on cash and cash equivalents	1,292	149	NMF	(467)	162	NMF						
Net increase/(decrease) in cash and cash equivalents	49,023	(7,603)	NMF	29,964	2,435	NMF						
Cash and bank deposits, beginning	7,774	17,305	-55.1%	26,833	2,435	NMF						
Cash and bank deposits, beginning Cash and bank deposits, ending	56,797	9,702	-55.1% NMF	20,033	9,702	NMF						
cash and bank deposits, ending	50,191	5,702	NIVIP	50,191	5,102	INIVIE						

#### **Medical insurance business financial highlights**



Income statement           GEL thousands, unless otherwise noted         1H20         1H19         Change         2020         2019         Change														
GEL thousands, unless otherwise noted	1H20	1H19	Change	2Q20	2Q19	Change								
Revenue	34,559	36,366	-5.0%	16,491	18,873	-12.6%								
Costs of services	(26,571)	(31,916)	-16.7%	(11,506)	(16,233)	-29.1%								
Net insurance claims incurred	(25,375)	(30,501)	-16.8%	(10,955)	(15,587)	-29.7%								
Agents, brokers and employee commissions	(1,196)	(1,415)	-15.5%	(551)	(646)	-14.7%								
Gross profit	7,988	4,450	79.5%	4,985	2,640	88.8%								
Salaries and other employee benefits	(2,778)	(2,106)	31.9%	(1,551)	(1,189)	30.4%								
General and administrative expenses	(817)	(728)	12.2%	(300)	(373)	-19.6%								
General and administrative expenses excluding IFRS 16	(1,020)	(909)	12.2%	(393)	(469)	-16.2%								
Impairment of receivables	(1,044)	(217)	NMF	(734)	(114)	NMF								
Other operating income	(122)	567	NMF	(32)	355	NMF								
EBITDA	3,227	1,966	64.1%	2,368	1,319	79.5%								
EBITDA excluding IFRS 16	3,024	1,785	69.4%	2,275	1,223	86.0%								
EBITDA margin excluding IFRS 16	8.8%	4.9%	3.8ppts	13.8%	6.5%	7.3ppts								
Depreciation and amortization	(576)	(548)	5.1%	(295)	(279)	5.7%								
Depreciation and amortization excluding IFRS 16	(394)	(380)	3.7%	(205)	(191)	7.3%								
Net interest income (expense)	764	286	NMF	403	173	NMF								
Net interest income (expense) excluding IFRS 16	793	313	NMF	417	186	NMF								
Net gains/(losses) from foreign currencies	(32)	18	NMF	41	(41)	NMF								
Net gains/(losses) from foreign currencies excluding IFRS 16	8	71	-88.7%	2	8	-75.0%								
Net non-recurring income/(expense)	(158)	-	NMF	(158)	-	NMF								
Profit before income tax expense	3,225	1,722	87.3%	2,359	1,172	101.3%								
Income tax benefit/(expense)	(603)	(288)	NMF	(398)	(203)	96.1%								
Profit for the period	2,622	1,434	82.8%	1,961	969	102.4%								
Attributable to:														
- shareholders of the Company	2,622	1,434	82.8%	1,961	969	102.4%								
Profit for the period excluding IFRS 16	2,670	1,501	77.9%	1,933	1,023	89.0%								
Attributable to:														
- shareholders of the Company	2,670	1,501	77.9%	1,933	1,023	89.0%								

### Medical insurance business financial highlights (cont'd)



Statement of	cash flo	w		Balance sheet								
GEL thousands, unless otherwise noted	1H20	1H19	Change	2Q20	2Q19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	Change	Jun-19	Change
Cash flows from / (used in) operating activities						5	Total assets, of which:	91,993	79,575	15.6%	89,905	2.3%
Revenue received	33,860	34,567	-2.0%	15,616	20,924	-25.4%	Cash and bank deposits	21,284	16,583	28.3%	14,228	49.6%
Cost of services paid	(23,436)	(25,820)	-9.2%	(9,910)	(14,941)	-33.7%	Insurance premiums receivable	38,955	31,531	23.5%	48,135	-19.1%
Gross profit received	10,424	8,747	19.2%	5,705	5,983	-4.6%	Property and equipment	14,890	15,054	-1.1%	15,159	-1.8%
Salaries paid	(4,823)	(4,389)	9.9%	(3,056)	(2,886)	5.9%	Right of use assets	603	597	1.0%	780	-22.7%
General and administrative expenses paid	(1,076)	(843)	27.6%	(368)	(490)	-25.0%	Goodwill and other intangible assets	5,517	5,519	NMF	5,488	0.5%
General and administrative expenses paid, excluding IFRS 16	(1,279)	(1,024)	24.9%	(461)	(586)	-21.4%	Inventory	198	-	NMF	-	NMF
Other operating income/(expense) and tax paid	(182)	(213)	-14.6%	(182)	(109)	66.8%	Prepayments	1,102	520	NMF	705	56.4%
Net cash flows from operating activities before income tax	4,343	3,302	31.5%	2,100	2,498	-15.9%	Other assets of which:	9,444	9,771	-3.3%	5,411	74.5%
Income tax paid	(1,130)	-	NMF	(230)	-	NMF	securities and intercompany loans	8,012	7,649	4.7%	3,118	NMF
Net cash flows from operating activities	3,213	3,302	-2.7%	1,870	2,498	-25.1%	Total liabilities, of which:	61,740	52,695	17.2%	64,764	-4.7%
Net cash flows from operating activities, excluding IFRS 16	3,010	3,121	-3.6%	1,777	2,401	-26.0%	Borrowed Funds	9,255	7,450	24.2%	5,651	63.8%
							Accounts payable	368	-	NMF	-	NMF
Cash flows from / (used in) investing activities							Insurance contract liabilities	40,048	31,687	26.4%	47,640	-15.9%
Cash outflow on Capex	(172)	(29)	NMF	(97)	-	NMF	Other liabilities	12,069	13,558	-11.0%	11,474	5.2%
Interest income received	1,289	836	54.2%	788	577	36.6%	Total shareholders' equity	30,253	26,880	12.5%	25,141	20.3%
Other investing activities	(303)	(1,308)	-76.8%	(628)	(300)	109.2%						
Net cash flow used in investing activities	814	(501)	NMF	63	277	-77.1%						
·												
Cash flows from / (used in) financing activities												
Payment of dividends	(750)	-	NMF	(375)	-	NMF						
Purchase of treasury shares	(155)	(143)	8.4%	(155)	(143)	8.4%						
Payment of finance lease liabilities	(174)	(154)	13.0%	(79)	(74)	7.3%						
Interest expense paid on finance lease	(29)	(27)	7.4%	(14)	(23)	-38.2%						
Increase/(decrease) in borrowings	1,600	(300)	NMF	-	(300)	NMF						
Interest expense paid	(260)	(315)	-17.5%	(187)	(134)	39.7%						
Net cash flows (used in)/from financing activities	232	(939)	NMF	(810)	(673)	20.3%						
Net cash flows (used in)/from financing activities, excluding IFRS 16	435	(758)	NMF	(717)	(577)	24.3%						
Effect of exchange rates changes on cash and cash equivalents	442	3	NMF	63	3	NMF						
Net increase/(decrease) in cash and cash equivalents	4,701	1,865	NMF	1,186	2,104	NMF						
Cash and bank deposits, beginning	16,583	12,363	34.1%	20,098	12,124	65.8%						
Cash and bank deposits, ending	21,284	14,228	49.6%	21,284	14,228	49.6%						

#### **GHG selected ratios and KPIs**



Selected ratios and KPIs	2Q20	2Q19	Change	1H20	1H19	Change	Selected ratios and KPIs	2Q20	2Q19	Change	1H20	1H19	Change
GHG, consolidated ROIC (%) Group rent expenditure of which, pharmacy and distribution business Group capex (maintenance) Group capex (development)	7.7% 5,770 5,389 2,319 4,183	12.2% 6,118 5,555 3,878 7,282	-4.5ppts -5.7% -3.0% -40.2% -42.6%	9.8% 12,257 11,537 5,537 10,708	12.2% 12,014 10,880 7,062 13,603	-2.4ppts 2.0% 6.0% -21.6% -21.3%	Diagnostics EBITDA margin excluding IFRS 16 impact Number of patients served ('000) Number of tests performed ('000) Average revenue per test GEL Average number of tests per patient	1.5% 106 266 6.7 2.5	4.3% 60 184 6.1 3.1	-2.8ppts 76.7% 44.6% 9.8% 18.2%	-3.5% 245 591 5.8 2.4	4.2% 127 356 6.4 2.8	-7.7ppts 92.90% 66.00% -9.40% -14.30%
Number of employees Number of physicians Number of nurses Nurse to doctor ratio, referral hospitals Number of pharmacists	15,555 3,476 3,301 0.95 2,887	16,173 3,645 3,425 0.94 2,983	-3.8% -4.6% -3.6% 1.1% -3.2%	15,555 3,476 3,301 0.95 2,887	16,173 3,645 3,425 0.94 2,983	-3.8% -4.6% -3.6% 1.1% -3.2%	<b>Pharmacy and Distribution</b> EBITDA margin excluding IFRS 16 Number of bills issued (millions) Average bill size Revenue from wholesale as a percentage of total revenue from pharma	10.5% 5.7 17.6 25.4%	10.3% 7.1 14.2 29.0%	0.2ppts - 19.0% 23.9% -3.6ppts	10.5% 13.4 16.5 26.0%	10.5% 14.2 13.8 29.0%	NMF -5.9% 19.6% -3.0ppts
Hospitals EBITDA margin excluding IFRS 16 Direct salary rate (direct salary as % of revenue) Materials rate (direct materials as % of revenue) Administrative salary rate (administrative salaries as % of	13.8% 36.3% 20.0% 14.9%	25.4% 35.3% 16.5% 11.0%	-11.6ppts 1.0ppts 3.5ppts 3.9ppts	17.7% 35.8% 19.6% 13.1%	25.5% 34.5% 17.0% 10.8%	-7.8ppts 1.3ppts 2.6ppts 2.3ppts	Revenue from retail as a percentage of total revenue from pharma Revenue from para-pharmacy as a percentage of retail revenue from pharma	74.6% 38.7%	71.0% 31.4%	3.6ppts 7.3ppts	74.0% 34.0%	71.0% 30.3%	3.0ppts 3.7ppts
revenue) SG&A rate (SG&A expenses as % of revenue)	5.7%	5.2%	0.5ppts	5.0%	4.9%		Number of pharmacies	299	279	20	299	279	20
Number of hospitals Number of hospital beds Hospitals bed occupancy rate Hospitals bed occupancy rate, excluding TRH and CMC CMC bed occupancy rate TRH bed occupancy rate Average length of stay (days) Average revenue per hospital bed	18 2,967 43.3% 43.6% 34.2% 49.3% 5.8 75.4	18 2,967 59.6% 64.1% 38.6% 46.9% 5.4 100.1	NMF NMF - 16.3ppts - 20.5ppts - 4.4ppts 2.4ppts 7.4% - 24.7%	18 2,967 51.9% 53.6% 37.6% 52.6% 5.6 85.4	18 2,967 60.9% 65.6% 37.1% 49.5% 5.4 100.4		Commission ratio Combined ratio excluding IFRS 16	66.4% 21.0% <i>3.3%</i> 87.4% 77.1%	82.6% 11.9% <i>3.4%</i> 94.5% 81.3%	- 16.2ppts 9.1ppts -0.1ppts -7.1ppts -4.2ppts	73.4% 19.0% <i>3.5%</i> 92.4% 71.3%	83.9% 12.3% 3.9% 96.1% 77.5%	- 10.5ppts 6.7ppts -0.4ppts -3.7ppts -6.2ppts
Clinics EBITDA margin excluding IFRS 16 EBITDA margin of polyclinics excluding IFRS 16 Direct salary rate (direct salary as % of revenue) Materials rate (direct materials as % of revenue) Number of community clinics Number of community clinics beds Number of polyclinics	13.1% 12.3% 34.3% 7.0% 19 353 15	17.5% 16.3% 34.8% 6.6% 19 353 16	-4.4ppts -4.0ppts -0.5ppts 0.4ppts NMF NMF -1	16.8% 13.2% 34.0% 6.5% 19 353 15	18.1% 15.6% 34.7% 6.4% 19 353 16	- 1.3ppts -2.4ppts -0.7ppts 0.1ppts NMF NMF -1							

### Water utility business financial highlights



Income staten	nent			Statement of cash flow				Balance sheet					
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	Change		
Revenue from water supply to legal entities	35,537	43,337	-18.0%	Cash received from customers	63,348	74,035	-14.4%	Inventories	4,204	3,799	10.7%		
Revenue from water supply to individuals	19,329	19,507	-0.9%	Cash paid to suppliers	(18,349)	(16,745)	9.6%	Trade and other receivables	21,689	22,357	-3.0%		
Revenue from electric power sales	2,354	8,240	-71.4%	Cash paid to employees	(10,037)	(9,103)	10.3%	Prepaid taxes other than income tax	2,107	50	NMF		
Revenue from technical support	1,955	1,607	21.7%	Interest received	1,052	592	77.7%	Prepayments	2,350	3,703	-36.5%		
Other income	1,594	1,850	-13.8%	Taxes paid	(7,347)	(4,056)	81.1%	Other current assets	-	7	NMF		
Revenue	60,769	74,541	-18.5%	Cash flow from operating activities before	28,667	44,723	-35.9%	Cash and cash equivalents	41,897	26,581	57.6%		
Salaries and benefits	(9,133)	(9,936)	-8.1%	maintenance capex Maintenance capex	(11,388)	(11,093)	2.7%	Total current assets	72,247	56,497	27.9%		
Electricity and transmission costs	(8,559)	(8,380)	2.1%	Operating cash flow	(11,300) <b>17,279</b>	(11,095) <b>33,630</b>		Property, plant and equipment	541,778	522,702	3.6%		
Other operating expenses	(10,621)	(11,350)	-6.4%	Purchase of PPE and intangible assets	(27,994)	(27,883)	- <b>40.0%</b>	Investment Property	8,641	8,641	NMF		
Operating expenses	(28,313)	(29,666)	-4.6%	3	(27,334)	(27,003)	0.4% NMF	Intangible assets	2,540	1,954	30.1%		
Provisions for doubtful trade receivables	(2,849)	(4,508)	-36.8%	Proceeds from PPE and investment property sale CAPEX VAT	- 2.323	3,653		Other non-current assets	2,647	1,243	NMF		
EBITDA	29,608	40,367	-26.7%	Restricted cash in Bank	2,323	3,653	-36.4% NMF	Total non-current assets	555,606	534,539	3.9%		
EBITDA Margin	48.7%	54.2%	-5.5ppts	Total cash used in investing activities	(25,671)		7.7%	Total assets	627,853	591,036	6.2%		
Depreciation and amortization	(17,456)	(16,936)	3.1%	Proceeds from borrowings	,	(23,826) 29,830	86.4%	Current borrowings	33,710	25,954	29.9%		
EBIT	12,151	23,431	-48.1%	Repayment of borrowings	55,616	(9,169)	38.2%	Trade and other payables	22,725	20,868	8.9%		
EBIT Margin	20.0%	31.4%	-11.4ppts	1 5 5	(12,672)			Other current liabilities	1,411	3,463	-59.3%		
Net interest expense	(15,808)	(10,793)	46.5%	Interest paid Dividend paid	(17,423)	(11,785)	47.8% NMF	Total current liabilities	57,846	50,285	15.0%		
Net non-recurring expenses	(489)	(2,389)	-79.5%	Contributions under share-based payment plan	(3)	- (1 777)		Long term borrowings	397,898	353,021	12.7%		
Foreign exchange (loss) gain	(9,954)	(9,497)	4.8%		(724)	(1,777)		Deferred income	30,025	29,435	2.0%		
EBT	(14,100)	752	NMF	Total cash flow from financing activities	24,794	7,099	NMF	Total non-current liabilities	427,923	382,456	11.9%		
Profit	(14,100)	752	NMF	Effect of exchange rates changes on cash	(1,086)	80		Total liabilities	485,769	432,741	12.3%		
				Total cash (outflow)/inflow	15,316	16,983		Total equity	142,084	158,295	-10.2%		
				Cash, beginning balance	26,581	13,713	93.8%	Total liabilities and equity	627,853	591,036	6.2%		
				Cash, ending balance	41,897	30,696	36.5%						

# Housing development business financial highlights



Income stat	ement			Statement of cash flow ange GEL thousands, unless otherwise noted 1H20 1H19 Change				Balance s	sheet		
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	Jun-20	Jun-19	Change
Gross profit from apartments sale Gross profit from construction	7,649 3,269	1,998 2,459	NMF 32.9%	Proceeds from sales of apartments Outflows for development	56,835 (18,494)	14,902 (15,213)	NMF 21.6%	Cash and cash equivalents Amounts due from credit institutions	13,958 7,131	3,335 422	NMF NMF
management Other income	(222)	290	NMF	Net proceeds from construction services Cash paid for operating expenses	1,837 (7,914)	4,074 (13,385)	-54.9% -40.9%	Investment securities Accounts receivable and other loans	202 17.036	1,305 13,114	-84.6% 29.9%
Gross Real Estate Profit Operating expenses	10,696 (6,754)	4,747 (6,847)	NMF -1.4%	Income tax paid Net cash flows from operating activities	(7,717) <b>24,547</b>	(7,080) ( <b>16,703</b> )	-9.0%	Prepayments Inventories	51,047 163,345	34,479 93,730	48.1% 74.3%
EBITDA Profit before non-recurring items	3,942 (3,231)	(2,100) (7,472)	NMF 56.8%	Capital expenditure on investment property and PPE Purchase of investment properties	(1,923)	(2,980)	-35.5% NMF	Investment property Land bank	2,311	38,346 9,359	-94.0% -86.3%
Net non-recurring items <b>Profit</b>	(309) <b>(3,539)</b>	(7,848)	NMF 54.9%	Loan issued Net cash flows used in investing activities	(300) (2,094)	(1,289) <b>(4,269)</b>	-76.7%	Commercial real estate Property and equipment	1,028 28,168	28,987 11,027	-96.5% NMF
				Net Intersegment loans received/(issued) Contributions under share-based payment plan	(9,427)	19,526	NMF -31.2%	Other assets	49,703 332,901	32,656 228,414	52.2%
				Interest paid Repayment of lease liabilities	(6,543)	(3,550)	84.3% NMF	Amounts due to credit institutions Debt securities issued	81,926 107,959	50,647 72,797	61.8% 48.3%
				Interest paid on lease liabilities Net cash flows from financing activities <sup>1</sup>	(30) (17.006)	- 14,989	NMF	Deferred income Other liabilities	97,864 55,147	21,249 49,109	NMF 12.3%
				Exchange (losses)/gains on cash equivalents	40 5.487	(726) ( <b>6,709)</b>	NMF	Total liabilities	342,896 (9,994)	193,802 34,623	76.9%
				Cash, beginning balance Cash, ending balance	15,602 21,089	(8,709) 10,467 3,758	49.1% NMF	Total liabilities and equity	(9,994) 332,902	228,425	45.7%

# **P&C insurance business financial highlights**



Income state	ment_			Statement of casl		Balance sheet						
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	change	
Gross premiums written	56,000	52,739	6.2%	Insurance premium received	38,761	39,224	-1.2%	Cash and cash equivalents	4,255	3,421	24.4%	
Earned premiums, gross	46,692	46,512	0.4%	Reinsurance premium paid	(5,138)	(4,044)	27.1%	Amounts due from credit institutions	39,012	32,574	19.8%	
Earned premiums, net	34,668	36,288	-4.5%	Insurance benefits and claims paid	(24,216)	(13,682)	77.0%	Investment securities	8,018	7,109	12.8%	
Insurance claims expenses, gross	(15,274)	(21,353)	-28.5%	Reinsurance claims received	10,773	5,096	NMF	Insurance premiums receivable, net	50,726	36,730	38.1%	
Insurance claims expenses, net	(15,198)	(15,111)	0.6%	Acquisition costs paid	(3,824)	(4,355)	-12.2%	Ceded share of technical provisions	68,673	64,706	6.1%	
Acquisition costs, net	(4,463)	(5,736)	-22.2%	Salaries and benefits paid	(5,393)	(6,775)	-20.4%	PPE and intangible assets, net	14,077	14,448	-2.6%	
Net underwriting profit	15,007	15,441	-2.8%	Interest received	2,231	1,888	18.2%	Goodwill	13,063	13,062	NMF	
Investment income	2,957	2,282	29.6%	Net other operating exepnses paid	(2,545)	(1,342)	89.7%	Deferred acquisition costs	3,796	3,812	-0.4%	
Net fee and commission income	40	57	-29.8%	Income tax paid	(746)	(1,343)	-44.5%	Pension fund assets	5,305	4,868	9.0%	
Net investment profit	2,997	2,339	28.1%	Net cash flows from operating activities	9,903	14,667	-32.5%	Other assets	20,343	19,544	4.1%	
Salaries and employee benefits	(4,839)	(5,391)	-10.2%	Purchase of property and equipment	(311)	(637)	-51.1%	Total assets	227,269	200,274	13.5%	
Selling, general and administrative expenses	(2,034)	(1,965)	3.5%	Purchase of intangible assets	(763)	(838)	-8.9%	Gross technical provisions	106,551	100,886	5.6%	
Depreciation & Amortisation	(1,153)	(994)	16.0%	Loan Issued	(4,310)	(19,902)	-78.3%	Other insurance liabilities	29,028	15,714	84.7%	
Impairment charges	(353)	(289)	22.1%	Proceeds from repayment of loan issued	3,310	21,166	-84.4%	Current income tax liabilities	522	376	38.7%	
Net other operating income	211	377	-44.1%	Proceeds from / (Placement of) bank deposits	(6,208)	(9,512)	-34.7%	Pension benefit obligations	5,305	4,868	9.0%	
Operating profit	9,836	9,518	3.3%	Purchase of available-for-sale assets/ Deposits	(20)	(1,784)	-98.9%	Other Liabilities	15,384	15,819	-2.8%	
Foreign exchange (loss) / gain	8	339	-97.7%	Net cash flows from used in investing activities	(8,303)	(11,507)	-27.8%	Total liabilities	156,790	137,663	13.9%	
Interest expense	(139)	(70)	97.8%	Dividend Paid	-	(8,000)	NMF	Total equity	70,479	62,611	12.6%	
Non-recurring expenses	(50)	-	NMF	Purchase of treasury shares	(521)	(927)	-43.8%	Total liabilities and equity	227,269	200,274	13.5%	
Pre-tax profit	9,655	9,787	-1.3%	Interest paid	(54)	-	NMF					
Income tax expense	(1,501)	(1,479)	1.5%	Cash paid for lease liabilities	(266)	(955)	-72.2%					
Net profit	8,154	8,308	-1.8%	Net cash flows from financing activities	(841)	(9,881)	-91.5%					
				Effect of exchange rates changes on cash and cash equivalents	72	(14)	NMF					
				Total cash inflow/(outflow)	831	(6,735)	NMF					
				Cash and cash equivalents, beginning	3,421	11,103	-69.2%					
				Cash and cash equivalents, ending	4,252	4,368	-2.7%					

### **Renewable energy business financial highlights**

Cash, beginning balance

Cash, ending balance



Income stat	tement			Statement of ca	Balance sheet						
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	Change
Revenue from electricity sales	16,183	2,395	NMF	Cash receipt from customers	25,049	639	NMF	Total current assets	70,076	88,794	-21.1%
Other revenue	2,703	-	NMF	Cash paid to suppliers	(4,393)	(349)	NMF	Property, plant and equipment	369,178	338,169	9.2%
Total Revenue	18,886	2,395	NMF	Cash paid to employees	(950)	(237)	NMF	Other non-current assets	14,173	12,491	13.5%
Salaries and benefits	(749)	(219)	NMF	Interest received	363	111	NMF	Total non-current assets	383,351	350,660	9.3%
Electricity and transmission costs	(90)	(20)	NMF	Taxes paid	(2,326)	(753)	NMF	Total assets	453,427	439,454	3.2%
Other operating expenses	(3,956)	(671)	NMF	Cash flow from operating activities	17,743	(589)	NMF	Total current liabilities	25,401	34,877	-27.2%
Total Operating Expenses	(4,796)	(910)	NMF	Purchase of PPE and intangible assets	(18,502)	(21,754)	-15.0%	Long term borrowings	270,501	254,792	6.2%
EBITDA	14,090	1,485	NMF	VAT return	2,500	3,210	-22.1%	Other non-current liabilities	2,239	2,175	2.9%
EBIT	7,562	587	NMF	Loans issued	(1,442)	(577)	NMF	Total non-current liabilities	272,740	256,967	6.1%
Net interest expense	(10,946)	(1,498)	NMF	Acquisition of subsidiaries	(6,008)	-	NMF	Total liabilities	298,141	291,844	2.2%
Non-recurring expenses	-	(151)	NMF	Total cash flow used in investing activities	(23,452)	(19,121)	22.6%	Total equity attributable to shareholders of the Group	156,006	111,113	40.4%
Foreign exchange (losses) gains	(1,049)	16	NMF	Proceeds from borrowings	-	28,176	NMF	Non-controlling interest	(720)	36,497	NMF
Profit before income tax	(4,433)	(1,046)	NMF	Repayment of borrowings	(2,472)	-	NMF	Total equity	155,286	147,610	5.2%
Net Profit	(4,433)	(1,046)	NMF	Interest paid	(8,493)	-	NMF	Total liabilities and equity	453,427	439,454	3.2%
Attributable to:				Dividends paid out	(4,927)	-	NMF	Total habilities and equity	433,427	433,434	3.270
- shareholders of the Group	(3,679)	(680)	NMF	Capital increase	5,591	2,415	NMF				
- non-controlling interests	(754)	(366)	NMF	Total cash flow used in financing activities	(10,301)	30,591	NMF				
				Exchange (losses)/gains on cash equivalents	1,953	1,623	20.3%				
				Total cash inflow/(outflow)	(14,057)	12,504	NMF				

NMF

1.5%

8,388

20,892

35,253

21,196

# **Hospitality & Commercial RE business financial highlights**



Jun-19

7.347

29,902

294,758

55,606

239,152

42,230

374.638

102,203

86,257

190,440

184,199

184.199

374,639

1.980

401

Change

-61.1%

-13.0%

NMF

13.7%

-2.6%

17.5%

NMF

NMF

-69.4%

3.0%

16.8%

5.8%

NMF

29.6%

-24.9%

-24.5%

NMF

3.0%

Jun-20

2.859

26,000

335,163

54,185

280,978

7,064

1.098

12,906

385.861

119,346

91,232

36.227

246,805

138,332

139.056

385,861

724

Non-controlling interest

Total liabilities and equity

Total equity

9,427

(5,262)

(392)

(44)

60

3,932

(16,385)

19,245

2.860

(19.526)

(7,792)

31,567

(21,269)

28,616

7.347

(126)

-

NMF

NMF

NMF

NMF

23.0%

-32.7%

-61.1%

-87.5%

-32.5%

771

Income sta	tement			Statement of cas	sh flow			Balances	sheet
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	Jun-2
Revenue from operating lease Gross profit from operating leases Revenue from hospitality services	5,670 <b>4,181</b> 3,294	4,034 <b>2,791</b> 3,134	40.6% <b>49.8%</b> 5.1%	Net proceeds from rent generating assets Net proceeds from hospitality services Other operating expenses paid	3,023 (1,143) (2,824)	1,924 822 (2,423)	57.1% NMF 16.5%	Cash and cash equivalents, bank placements Prepayments Inventories	2,8 26,00 7
Gross profit from hospitality services Other income	<b>(1,094)</b> 61	697 -	NMF NMF	Income tax paid Net cash flows from operating activities	(586) <b>(1,529)</b>	- 324	NMF NMF	Investment property Land bank	335,1 <i>54,1</i>
Gross Real Estate Profit Revaluation of commercial and	<b>3,148</b> (117,578)	<b>3,488</b> 7,892	<b>-9.7%</b> NMF	Acquisition of investment property Capital expenditure on investment property	5,976 (31,593)	(10,574) (18,741)	NMF 68.6%	Commercial real estate Property and equipment	280,9 7.0
hospitality properties Operating expenses NOI	(3,166) (117,596)	(1,860) 9,520	70.2% NMF	VAT return Loans issued	6,769	(9,787) (58)	NMF NMF	Goodwill Other assets	1,0 1,0 12,9
Not Net operating income before non- recurring items	(117,598) (122,627)	5,880	NMF	Acquisition of subsidiaries Net cash flows used in investing activities	- (18,848)	(13,874) <b>(53,035)</b>	NMF - <b>64.5%</b>	Total assets Borrowings	<b>385,8</b> 119,34
Net non-recurring items Profit before income tax	(1,212) <b>(123,839)</b>	- 5,880	NMF NMF	Proceeds from preferred stock issued Proceeds from debt securities issued	1,137 -	6,833 59,964	-83.4% NMF	Debt securities issued Other liabilities	91,23 36,22
Profit / (loss)	(123,839)	5,880	NMF	Contributions under share-based payment plan Proceeds from borrowings	(679) 231	(172) 67,941	NMF -99.7%	Total liabilities Total equity attributable to	246,80 138,33
				Repayment of borrowings	(487)	(75,681)	-99.4%	shareholders of the Group	130,3

Net intragroup loans (repaid)/ received

Net cash flows from financing activities<sup>1</sup>

Effect of exchange rate changes on cash and cash

Repayment of lease liabilities

Interest paid on lease liabilities

Total cash inflow/(outflow)

Cash, beginning balance

Cash, ending balance

Interest paid

equivalents

### **Beverages business financial highlights**

NMF

-19.3%

-19.3%

-

(24,759)

(24,759)

(19,984)

(19,984)

Net non-recurring items

(Loss) Profit

(Loss) profit before income tax



	- 4 - 10 - 10 4	Delence cheet (M	Delense sheet (Deer business)								
Income sta	atement			Balance sheet (W	Balance sheet (Beer business)						
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	change
Wine Business	16,120	17,967	-10.3%	Cash and cash equivalents	4,650	5,230	-11.1%	Cash and cash equivalents	7,499	2,543	NMF
Beer Business	29,472	20,425	44.3%	Amounts due from financial institutions	946	994	-4.8%	Accounts Receivable	11,036	7,912	39.5%
Distribution Business	8,675	7,834	-10.7%	Accounts Receivable	15,413	14,269	8.0%	Prepayments & Other Assets	3,085	4,489	-31.3%
Revenue	54,267	46,226	17.4%	Prepayments & Other Assets	3,035	2,748	10.4%	Inventory	11,550	12,113	-4.6%
Wine Business	(10,058)	(9,306)	8.1%	Inventory	26,320	28,174	-6.6%	Intangible Assets, Net	6,635	8,722	-23.9%
Beer Business	(19,705)	(14,223)	38.5%	Intangible Assets, Net	174	270	-35.6%	Goodwill	-	2,226	NMF
Distribution Business	(6,398)	(6,033)	6.1%	Goodwill	10,803	10,803	NMF	Property and Equipment, Net	72,454	70,249	3.1%
COGS	(36,162)	(29,562)	22.3%	Property and Equipment, Net	55,858	57,138	-2.2%	Total Assets	112,259	108,254	3.7%
Gross Profit	18,104	16,664	8.6%	Total Assets	117,199	119,626	-2.0%	Accounts Payable	12,084	10,491	15.2%
Gross Profit Margin	33.4%	<b>36.0</b> %	-2.6ppts	Accounts Payable	7,630	4,342	75.7%	Borrowings	99,211	88,973	11.5%
Salaries and other employee benefits	(8,665)	(9,907)	-12.5%	Borrowings	50,258	49,373	1.8%	Other Current Liabilities	4,322	2,933	47.4%
Sales and marketing expenses	(963)	(2,697)	-64.3%	Other Current Liabilities	3,519	4,188	-16.0%	Total Liabilities	115,617	102,397	12.9%
General and administrative expenses	(3,267)	(4,205)	-22.3%	Total Liabilities	61,407	57,903	6.0%	Total equity	(3,358)	5,857	NMF
Distribution expenses	(2,633)	(3,112)	-15.4%	Total equity	55,792	61,723	-9.6%	Total liabilities and equity	112,259	108,254	3.7%
Other operating expenses	(301)	(1,474)	-79.6%	Total liabilities and equity	117,199	119,626	-2.0%				
EBITDA	2,275	(4,731)	NMF								
wine EBITDA	1,281	3,046	-57.9%								
beer EBITDA	19	(6,464)	NMF								
distribution EBITDA	1,115	(985)	NMF								
Net foreign currency gain (loss)	(7,881)	(6,525)	20.8%								
Depreciation and amortization	(7,732)	(7,232)	6.9%								
Net interest income/expense	(6,646)	(6,271)	6.0%								

### **Beverages business financial highlights (cont'd)**



1H19

21,802

(11,775)

(982)

(4,432)

(13,396)

(8,783)

(15,810)

(15,810)

88,719

(68,658)

(3,522)

10,143

26,683

(278) 1,811

1,244

3.055

Change

38.7%

-33.2%

72.1%

-89.4%

32.6%

NMF

-80.9%

-80.9%

-94.4%

NMF

13.6%

-50.7%

NMF -78.5%

-27.7%

NMF

NMF

NMF

Statement of cash flow (Wir	ne busine		Statement of cash flow (Bee	er busi	
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	1H
Cash received from customers	19,604	19,921	-1.6%	Proceeds from sales	30,2
Cash paid to suppliers	(5,003)	(8,505)	-41.2%	Cash outflows for inventory	(7,8
Cash paid to employees	(3,591)	(2,608)	37.7%	Transportation Cost	(1,6
Cash paid for operating expenses	(4,553)	(4,770)	-4.6%	Sales and Marketing Expenses	(4
Taxes paid	(1,984)	(2,242)	-11.5%	Operating Expenses	(17,7
Net cash flows from operating activities	4,475	1,797	NMF	Net cash flows from operating activities	2,4
Purchase of Property, Plant and Equipment	(1,036)	(3,844)	-73.1%	Cash outflows for purchase of Property, plant and equipment	(3,0
Net cash flows from used in investing activities	(1,036)	(3,844)	-73.1%	Net cash flows used in investing activities	(3,0
Proceeds from borrowings	612	18,545	-96.7%	Proceeds from borrowings	5,0
Repayments of borrowings	(3,024)	(18,115)	-83.3%	Repayment of borrowings	
Interest paid	(1,626)	(1,527)	6.5%	Interest paid	(4,0
Capital increase	-	226	NMF	Issue of share capital	5,0
Cash paid for lease liabilities	(367)	-	NMF	Cash paid for lease liabilities	(2
Net cash flows from financing activities	(4,405)	(871)	NMF	Net cash flows from financing activities	5,7
Effect of exchange rates changes on cash and cash equivalents	386	380	1.6%	Effect of exchange rate changes on cash and cash equivalents	(2
Total cash inflow/(outflow)	(580)	(2,538)	-77.2%	Total cash inflow/(outflow)	4,9
Cash and cash equivalents, beginning	5,230	8,380	-37.6%	Cash and cash equivalents at beginning of period	2,5
Cash and cash equivalents, ending	4,650	5,842	-20.4%	Cash and cash equivalents at end of period	7,4

# **Education business financial highlights**



Income state	ment			Statement of cash flow				Balance sheet				
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	change	
Revenues	13,955	12,235	14.1%	Cash receipts from customers	12,121	14,212	-14.7%	Cash and cash equivalents	7,138	5,128	39.2%	
Salaries and employee benefits	(7,177)	(5,391)	33.1%	Cash receipts from state	316	302	4.6%	Accounts Receivable	638	532	19.9%	
Other operating expenses	(1,601)	(2,085)	-23.2%	Cash paid to suppliers	(1,465)	(2,486)	-41.1%	Prepayments & Other Assets	2,248	1,666	34.9%	
EBITDA	5,177	4,759	8.8%	Cash paid to employees	(6,382)	(5,462)	16.8%	Inventory	166	100	66.0%	
EBITDA margin	37.1%	38.9%	1.8ppts	Interest received	74	63	17.5%	Intangible Assets, Net	54	54	NMF	
Foreign exchange gain / (loss)	(1,589)	(1,034)	53.7%	Net proceeds from restricted cash	400	-	NMF	Property and Equipment, Net	33,780	32,778	3.1%	
Depreciation and amortization	(1,008)	(935)	7.8%	Taxes paid	(197)	(295)	-33.2%	Total Assets	44,024	40,258	9.4%	
Net interest income/expense	(499)	(553)	-9.8%	Net cash flows from operating activities	4,867	6,334	-23.2%	Accounts Payable	4,404	4,245	3.7%	
Non-recurring expenses	-	(450)	NMF	Purchase of Property, Plant and Equipment	(3,064)	(1,290)	NMF	Borrowings	21,968	19,808	10.9%	
Net income before income tax	2,081	1,787	16.5%	Issue/repayment of loans	-	8	NMF	Other Current Liabilities	6,278	5,481	14.5%	
Net income	2,081	1,777	17.1%	Increase of capital in subsidiaries	-	(17)	NMF	Deferred revenue	11,925	13,295	-10.3%	
				Net cash flows from used in investing activities	(3,064)	(1,299)	NMF	Other Non-current Liabilities	481	544	-11.6%	
				Proceeds from borrowings	1,168	3,770	-69.0%	Total Liabilities	45,056	43,373	3.9%	
				Repayment of borrowings	(437)	(4,335)	-89.9%	Total equity	(1,032)	(3,115)	66.9%	
				Payment of finance lease liabilities	-	(160)	NMF	Total liabilities and equity	44,024	40,258	9.4%	
				Interest paid	(488)	(491)	-0.6%					
				Dividends paid	-	(54)	NMF					
				Net cash flows from financing activities	243	(1,270)	NMF					
				Effect of exchange (losses)/gains on cash and cash equivalents	(36)	53	NMF					
				Total cash inflow/(outflow)	2,010	3,818	-47.4%					
				Cash and cash equivalents at the beginning of period	5,128	2,621	95.7%					

7,138

6,439

10.9%

Cash and cash equivalents at the end of period

#### **Auto service business financial highlights**



Income statement				Statement of cash flo	Balance sheet						
GEL thousands, unless otherwise noted	1H20	1H19	Change	GEL thousands, unless otherwise noted		1H19	Change	GEL thousands, unless otherwise noted	Jun-20	Dec-19	Change
Revenue	16,031	5,304	NMF	Operating revenue received	15,594	5,296	NMF	Cash and cash equivalents	1,003	243	NMF
Costs of services	(12,240)	(2,281)	NMF	Salaries and benefits paid	(3,317)	(2,691)	23.3%	Accounts receivable	1,758	1,739	1.1%
Gross profit	3,791	3,023	25.4%	Operating expenses paid	(13,706)	(2,705)	NMF	Premises and equipment, net	47,098	45,988	2.4%
Salaries and other employee benefits	(1,761)	(955)	84.4%	Net cash flows from operating activities	(1,430)	(100)	NMF	Intangible assets, net	7,842	8,287	-5.4%
Selling, general administrative expenses	(1,328)	(1,426)	-6.9%	Purchase of property and equipment	(48)	(12,634)	-99.6%	Prepayments	1,477	4,228	-65.1%
Net other operating income / (expenses)	(22)	(28)	-22.4%	Purchase of intangible assets	-	(1,219)	NMF	Inventory	6,191	3,894	59.0%
Total operating expenses	(3,112)	(2,410)	29.1%	Loan Issued	(49)	22	NMF	Other Assets	438	1,515	-71.1%
EBITDA	680	613	10.9%	Net cash flows from used in investing activities	(97)	(13,831)	-99.3%	Total assets	65,806	65,895	-0.1%
Depreciation expense	(1,295)	(644)	NMF	Proceeds from borrowings	4,205	39,528	-89.4%	Borrowings	61,366	57,563	6.6%
Amortization expense	(467)	(357)	31.1%	Repayment of borrowings	(4,756)	(28,366)	-83.2%	Finance lease liability	4,050	3,493	16.0%
Interest expense	(2,250)	(2,409)	-6.6%	Interest paid	(809)	(2,131)	-62.0%	Accounts payable	2,314	1,717	34.8%
Foreign exchange gain / (loss)	(3,154)	(210)	NMF	Issue of ordinary shares	4,000	5,000	-20.0%	Other Liabilities	2,132	4,769	-55.3%
Non-recurring income / (costs)	(26)	(315)	-91.7%	Repayment of lease liabilities	(198)	(38)	NMF	Total liabilities	69,861	67,540	3.4%
Net profit	(6,512)	(3,321)	96.1%	Interest paid on lease liabilities	(133)	(54)	NMF	Share capital - ordinary shares	11,104	7,002	58.6%
				Net cash flows from financing activities	2,309	13,939	-83.4%	Retained earnings	(8,764)	(2,035)	NMF
				Effect of exchange rates changes on cash and cash equivalents	(23)	(14)	58.7%	Net profit	(6,512)	(6,729)	-3.2%
				Net increase/(decrease) in cash and cash equivalents	760	(6)	NMF	Total equity	(4,056)	(1,646)	NMF
				Cash and cash equivalents, beginning	238	1,465	-83.8%	Non-controlling interest	116	116	NMF
				Cash and cash equivalents, ending	997	1,459	-31.6%	Total liabilities and equity	65,806	65,895	-0.1%

#### Glossary



- GCAP refers to the aggregation of stand-alone Georgia Capital PLC and stand-alone JSC Georgia Capital accounts
- Georgia Capital and "the Group" refer to Georgia Capital PLC and its portfolio companies as a whole
- **NMF** Not meaningful
- NAV Net Asset Value, represents the net value of an entity and is calculated as the total value of the entity's assets minus the total value of its liabilities.
- LTM last twelve months
- NTM next twelve months
- **EBITDA** Earnings before interest, taxes, non-recurring items, FX gain/losses and depreciation and amortization; The Group has presented these figures in this document because management uses EBITDA as a tool to measure the Group's operational performance and the profitability of its operations. The Group considers EBITDA to be an important indicator of its representative recurring operations.
- ROIC return on invested capital is calculated as EBITDA less depreciation, divided by aggregate amount of total equity and borrowed funds
- IRR for portfolio companies is calculated based on a) historical contributions to the portfolio company less b) dividends received and c) market / fair value of the portfolio company at 30 June 2020.
- MOIC Multiple of Capital Invested is calculated as follows: i) the numerator is the cash and non-cash inflows from dividends and sell-downs plus fair value of investment at reporting date ii) the denominator is the gross investment amount.
- Realised MOIC Realised Multiple of Capital Invested is calculated as follows: i) the numerator is the cash and non-cash inflows from dividends and sell-downs ii) the denominator is the gross investment amount.
- Loss ratio equals net insurance claims expense divided by net earned premiums
- · Expense ratio in P&C Insurance equals sum of acquisition costs and operating expenses divided by net earned premiums
- · Combined ratio equals sum of the loss ratio and the expense ratio in the insurance business
- **ROAE** Return on average total equity (ROAE) equals profit for the period attributable to shareholders divided by monthly average equity attributable to shareholders of the business for the same period for BoG and P&C Insurance;
- · Net investment gross investments less capital returns (dividends and sell-downs)
- **EV** enterprise value
- NOI net operating income
- Liquid assets & loans issued include cash, marketable debt securities and issued short-term loans
- **Total return / value creation** total return / value creation of each portfolio investment is calculated as follows: we aggregate a) change in beginning and ending fair values, b) gains from realized sales (if any) and c) dividend income during period. We then adjust the net result to remove capital injections (if any) to arrive at the total value creation / investment return.
- WPP Wind power plant
- HPP Hydro power plant
- **PPA** Power purchase agreement

#### **Company information**



#### Georgia Capital PLC

Registered Address 84 Brook Street London W1K 5EH United Kingdom <u>www.georgiacapital.ge</u> Registered under number 10852406 in England and Wales

Stock Listing London Stock Exchange PLC's Main Market for listed securities Ticker: "CGEO.LN"

#### **Contact Information**

Georgia Capital PLC Investor Relations Telephone: +44 (0) 203 178 4052; +995 322 000000 E-mail: <u>ir@qcap.qe</u>

#### Auditors

Ernst & Young LLP 1 More London Place London, SE1 2AF United Kingdom

#### Registrar

Computershare Investor Services PLC The Pavilions Bridgwater Road Bristol BS13 8AE United Kingdom

Please note that Investor Centre is a free, secure online service run by our Registrar, Computershare, giving you convenient access to information on your shareholdings. Investor Centre Web Address - <u>www.investorcentre.co.uk</u>. Investor Centre Shareholder Helpline - + 44 (0) 370 702 0176

#### Share price information

Shareholders can access both the latest and historical prices via the website www.georgiacapital.ge

